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Abstract 
35 million people died due to the acquired immunodeficiency syndrome (AIDS) since 
the outbreak of the HIV pandemic. Despite intensive research, developing an immu-
nogen to induce broadly neutralizing antibodies (bnAbs) against HIV remains a chal-
lenge, although about 10 - 30 % of infected individuals develop bnAbs against HIV-1 
on average 2.5 years after infection. Two of them are 2F5 and 4E10, targeting the 
membrane proximal external region (MPER) of the transmembrane envelope protein 
(TM) gp41. Previous studies on the non-pathogenic retrovirus feline foamy virus 
(FFV) revealed immunogenic regions with a bipartite motif in its TM protein, gp48, 
equivalent to the locations of the 2F5 and 4E10 epitopes in HIV gp41. In order to use 
the FFV TM protein as HIV epitope scaffold, the 2F5 and 4E10 epitopes were inte-
grated into the full-length FFV Env backbone by replacing the equivalent sequences. 
After transfection of HEK293T cells, it could be shown that the chimeric FFV/HIV-1 
proteins are produced and released into the cell culture supernatants. Furthermore, 
the secreted material has properties typical for subviral particles (SVPs). This is in 
line with the finding that FFV Env protein expression is sufficient to induce budding in 
absence of any other FV proteins. In order to allow evaluation of the potential of 
those hybrid SVPs as HIV-1 vaccines by administration in a DNA-prime/SVP-boost 
regimen in rats, sufficient amounts were required. In the frame of this thesis, efficient 
protocols for large-scale production of SVPs were established. This was achieved by 
subcloning the respective sequences into retroviral transfer vectors and systematic 
optimization of transfection, virus production and concentration protocols to obtain 
high titer stocks of infectious vesicular stomatitis virus protein G (VSV-G) pseudo-
typed viruses. Transduction of various cell lines revealed CRFK cells as suitable pro-
ducer cells for the production of the intended SVPs. Immunoprecipitation of the native 
antigens with mAb 2F5 and mAb 4E10 demonstrated that the respective epitopes are 
accessible. Application of transmission electron microscopy using the method of 
negative staining confirmed successful SVP production which was further optimized 
by testing different commercially available expression media. First steps to scale up 
the production process using Corning® HYPERFlasks® have also been accom-
plished. The established protocols for large-scale production of hybrid FFV/HIV-1 
SVPs carrying the 2F5 and 4E10 epitopes allow testing the potential of a novel re-
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1 Introduction  
1.1 Human immunodeficiency virus-1  
1.1.1 HIV and AIDS 
Most likely, the acquired immunodeficiency syndrome (AIDS) was present in Africa 
for many decades. In 1981, it emerged in the human population as an outbreak of 
Pneumocystis carinii pneumonia among homosexual men in the United States [1]. 
AIDS is caused by the lentivirus HIV that belongs to the member of Retroviridae. The 
equivalent agent in apes and monkeys is the simian immunodeficiency virus (SIV). 
HIV is transmitted primarily by sexual intercourse, injection of infected blood or blood-
derived products and by mother-to-child transmission [2, 3].  
After an acute infection in which CD4+ T-cells are massively depleted in the genital 
tissue and the gut-associated lymphoid tissue (GALT), replication starts in resting 
CD4+ T-cells of the genital mucosa in the case of sexual transmission [4]. A chronic 
infection characterized by a progressively dying immune system follows [5].  
The first 10 days represent the initial phase or eclipse phase, when viral RNA is be-
low detection level in the blood circulation. It is followed by the acute phase which is 
characterized by high virus production in activated CD4+ T-cells (Figure 1) [6]. When 
control by the cellular immune system sets in, infection proceeds to an asymptomatic 
period in which CD4+ T-cell numbers slowly but steadily decline [3]. HIV-1 infection is 
associated by a chronic immune stimulation increasing T-cell turnover, production of 
pro-inflammatory cytokines and chemokines and activation of cytotoxic T-cells (CTLs) 
and polyclonal B-cells [5, 7]. As a consequence, the humoral immune response be-
gins to show weeks after infection, resulting in seropositivity. Together, CTL and anti-
body responses against HIV reduce the plasma viral load to a stable level, called the 
viral set point, at which patients are less infective than during the acute phase of in-
fection [8]. However, virus is never completely neutralized due to escape mutations of 
HIV. The asymptomatic phase can last from several months to more than 10 years 
before patients develop AIDS and finally die because of opportunistic infections with 











Figure 1: Time course of a HIV infection [3] 
During the acute phase of infection, the plasma viral load is highest because of ongoing replication in 
CD4
+
 T-cells. A chronic infection of the immune system follows where CD4
+
 T-cells continually die. 
Weeks after infection, the plasma viral load is reduced to a stable level because cytotoxic T-cells are 
activated and the humoral immune system sets in. Patients develop antibodies against HIV and be-
come seropositive. However, escape mutations prevent complete clearance of HIV. The chronic 
asymptomatic phase can last more than 10 years before opportunistic infections occur due to AIDS.  
Since the beginning of the epidemic, approximately 70 million people have been in-
fected and 35 million have died of AIDS. In 2011, 1.7 million people died of AIDS-
related illnesses worldwide and about 34 million people were living with HIV that con-
stitutes 0.8 % of the world population (Figure 2). However, sub-Saharan Africa re-
mains most severely affected as nearly 1 in every 20 adults (4.9 %) lives with HIV 
which accounts for 69 % of the people living with HIV worldwide [10]. 
 









1.1.2 Genome  
HIV is an enveloped single-stranded positive sense RNA virus with a genome of 9.5 
kb in length. Like all retroviruses, the genome encodes Gag (further cleaved into ma-
trix, capsid and nucleocapsid), Pol (cleaved into protease, reverse transcriptase and 
integrase) and Env (processed into gp120 and gp41) (Figure 3). 
 
Figure 3: HIV-1 genome organization [3] 
LTR: long terminal repeat, gag: group specific antigen, pol: polymerase, env: envelope protein, MA: 
matrix protein, CA: capsid protein, NC: nucleocapsid protein, PR: protease, RT: reverse transcriptase, 
IN: integrase, vif: viral infectivity factor, vpr: viral protein R, tat: transactivator of transcription, rev: regu-
lator of virion, vpu: viral protein U, gp120/41: glycoprotein120/41, nef: negative factor 
In addition, the HIV-1 genome encodes several accessory and regulatory proteins: 
Tat (trans-activator of transcription) increases the production of full length HIV-1 
mRNA transcripts that are packaged into viral particles. Transcriptional elongation is 
accomplished by binding to an RNA stem-loop structure (Tat activation region, TAR) 
at the 5’-terminus of the viral mRNA [11]. 
Rev (regulator of virion) facilitates the transport of unspliced viral mRNAs encoding 
Gag, Pol and Env from the nucleus to the cytoplasm by binding to the Rev-response 
element (RRE). It is responsible for regulating the switch from early transcription of 
regulatory proteins to late structural proteins [12]. 
Nef (negative factor) contributes to high viral loads and promotes activation of resting 
T-cells [13]. In uninfected bystander CD4+ T-cells it induces apoptosis [14, 15] and 
down-regulates CD4 and MHC-I. Therefore, infected cells can evade the immune 
system [16].  
Vif (viral infectivity factor) recruits ubiquitinating proteins to apolipoprotein B mRNA-









proteasomal degradation [17]. Human APOPEC3G is a cytidine deaminase that in-
duces multiple C-to-U deaminations in minus-strands of HIV-1 proviral DNA derived 
from viral particles carrying that enzyme [18].  
Vpr (viral protein R) induces cell cycle arrest in G2 and apoptosis. Furthermore, it al-
lows entry of the viral pre-integration complex into the nucleus of non-dividing cells 
[19].  
Vpu (viral protein U) antagonizes tetherin which inhibits the release of fully assem-
bled virions at the cell membrane [20]. Additionally, it targets CD4 to proteasomes for 
degradation [21]. 
1.1.3 Replication 
Primary targets of HIV-1 are CD4+ T-cells [22] and cells of the macrophage and 
monocyte lineage [4]. Binding of gp120 to the CD4 receptor triggers conformational 
changes leading to the exposure of the CCR5 or CXCR4 co-receptor binding sites. 
Which co-receptor is actually bound depends on the amino acid sequence of the V3 
loop of the SU domain (gp120). Further conformational changes in gp41 lead to the 
six-helix bundle-formation that initiates the fusion of the cellular and viral membranes 
(Figure 4) [23]. 
 
Figure 4: HIV-1 entry [24] 
Gp120 binds the CD4 receptor that triggers conformational changes resulting in co-receptor binding. 
The V3 loop of SU plays a role at the decision between the co-receptors, CCR5 or CXCR4. The fusion 
peptide of gp41 inserts into the host membrane. The subsequent sex-helix bundle-formation of gp41 









After release into the cytoplasm, active reverse transcriptase (RT) transforms the 
RNA genome into one pro-viral DNA copy (Figure 5). The provirus migrates into the 
host cell nucleus where it randomly integrates into the host cell genome. The cellular 
machinery transcribes the proviral DNA into spliced mRNAs for viral protein expres-
sion and into full-length single stranded RNA. Viral proteins and two copies of full-
length RNA are assembled to viral particles at the cell surface where they are re-
leased as immature and noninfectious virions [2]. Only after cleavage of Gag by viral 
protease, HIV particles acquire infectivity [25].  
 
Figure 5: Simplified replication cycle of HIV-1 [26] 
Binding of gp120 to CD4 receptor triggers the fusion process. After release of the viral RNA genome 
into the cytoplasm, reverse transcriptase produces proviral DNA that randomly integrates into the host 
cell genome. The cell machinery starts viral protein expression and the production of two full-length 
single stranded RNA copies. Virus particles are assembled at the cytoplasm membrane and bud as 
noninfectious virions. Viral protease cleaves Gag and thereby infectivity is acquired.  
Single HIV-1 particles (Figure 6) comprise an internal cone-shaped capsid (p24, CA) 
surrounded by a lipid membrane that is wrapped on a scaffold of matrix proteins 
(p17, MA). Approximately 15 trimers of gp160 (gp120 + gp41) form spikes on a single 
virion’s surface [27]. The lipid membrane originates from the virus-producing host 
cell. As a consequence, membrane proteins are embedded in the viral lipid bilayer. 
The CA contains two copies of the HIV RNA genome that are associated with the nu-











Figure 6: Structure of a single HIV-1 virion [3] 
MA: matrix, NC: nucleocapsid, CA: capsid, RT: reverse transcriptase, Nef: negative factor, Vif: viral in-
fectivity factor, Vpr: viral protein R 
1.1.4 HIV-1 Env and broadly neutralizing antibodies against the MPER of gp41 
The 160 kD glycoprotein Env (gp160) is synthesized in the rough endoplasmic reticu-
lum (Figure 7A) and cleaved into gp120 (SU) and gp41 (TM) by a cellular furin prote-
ase in the Golgi apparatus [28, 29]. Gp120 and gp41 assemble into hetero-trimers 













Figure 7: HIV-1 Env (gp160) [30] and  a single HIV-1 Env spike [31] 
A) Gp160 consists of the surface protein gp120, the transmembrane envelope protein gp41 and the 
signal peptide (SP). Gp120 and gp41 are cleaved by furin protease at the furin site after transportation 
to the Golgi apparatus. Depicted are the different regions of gp120 and gp41. Gp120 comprises five 
constant regions (C1-5) and five variable regions (V1-5). The gp41 protein contains a fusion peptide 
(FP), two helical regions (HR1, HR2), a membrane proximal external region (MPER) and a transmem-
brane domain (TMD). B) 3-dimensional structure of a single heterotrimeric HIV-1 envelope spike con-
sisting of gp120 and gp41. The approximate locations of the 2F5 (red) and 4E10 (blue) epitopes in the 
viral spike are indicated.  
After binding of gp120 to CD4 and the co-receptor, conformational changes of gp41 
cause the fusion peptide to intrude into the host cell membrane (Figure 4). The N-
terminal helical region (NHR) and the C-terminal helical region (CHR) interact to form 
the six-helix bundle formation (Figure 4 and 8) where the viral and host cell mem-
branes are in close proximity, immediately before fusion.  
So far, the development of an effective HIV-1 vaccine remained unsuccessful. Antivi-
ral immune mechanisms fail to clear the virus, although neutralizing antibodies 
(nAbs) are induced weeks after infection [32]. The viral load is merely reduced to a 
lower stable level (viral set-point, Figure 1). This is due to the fact that the virus la-









son is the high mutation rate of HIV-1 that produces escape mutations [33]. Never-
theless, minimally accessible epitopes targeted by broadly neutralizing antibodies 
(bnAbs) exist and 10 - 30 % of infected patients even develop bnAbs [34, 35] on av-
erage 2.5 years after infection [36-38]. Targets of bnAbs are the glycan structure, the 
V2/V3 loop, the CD4 binding site of the SU domain or regions of the TM domain. The 
conserved membrane proximal external region (MPER) [39] contains the epitopes 
recognized by four such bnAbs: Z13, 10E8, 2F5 and 4E10 with a neutralization 
breadth of <20 %, 97 %, 48 % and 88 %, respectively [40]. The relative positions of 
the 2F5 (ELDKWAS) and 4E10 (WFNITNWLW) epitope sequences [41] in the MPER 
are depicted in Figure 8. They neutralize HIV-1 in different stages of infection by in-
teracting with fusion intermediates of gp41. Accordingly, neutralization by 2F5 and 
4E10 occurs mainly after receptor binding because their epitopes are undisclosed in 
free virions. Furthermore, binding of the 2F5 and 4E10 epitopes hinders membrane 
fusion [42-44]. 
 
Figure 8: Functional domains of gp41 (TM) and their conformational changes during infection 
[41, 45]  
The gp41 protein consists of the fusion peptide (FP), the fusion peptide proximal region (FPPR), the 
N-terminal helical region (NHR), the immunosuppressive domain (isu), Cys-Cys-loop (C-C), the C-
terminal helical region (CHR) and the membrane proximal external region (MPER). C-terminally of the 
MPER are the membrane spanning domain (MSD) and the cytoplasmic tail (CT). The conserved 
epitopes recognized by the broadly neutralizing antibodies 2F5 (ELDKWAS) and 4E10 (WFNIT-
NWLW) are located within the MPER. In order to facilitate the fusion of viral and host cell membranes, 
gp41 undergoes conformational changes including an interaction of the NHR and CHR. The so called 









The MPER is important for both, the fusion process of the viral and host cell mem-
branes [39, 46, 47] and for the incorporation of Env into virions [39] by a cholesterol 
binding domain at the C-terminal end of the MPER (LWYIK) [48]. The close proximity 
of the MPER and the viral membrane implies that 2F5 and 4E10 might interact with 
the viral membrane during neutralization, thereby turning it into a key component of 
both epitopes [41]. It was shown that 2F5 and 4E10 have a long complementarity de-
termining region (CDR-H3) [49-52] that may interact with the viral membrane [49, 51]. 
As the FPPR and MPER interact during infection (Figure 8), they play a crucial role in 
infectivity [46]. The FPPR supports epitope binding and thereby affinity of 2F5 [47]. 
Infection mainly occurs via mucosal transmission in pluri-stratified epithelium (e.g., 
vagina, exocervix, foreskin and anus). Dendritic cells are the first targets of HIV-1 be-
fore dissemination in the submucosa follows [4, 53]. Interestingly, peripheral blood 
mononuclear cells (PBMC) infected with HIV-1 produce virus that is internalized by 
epithelial cells and cross the epithelial barrier by transcytosis [54]. HIV-1 binds to epi-
thelial cells using the alternative receptor glycosphingolipidgalactosylceramide. This 
interaction is mediated by the ELDKWA epitope of 2F5 that is also recognized by 
some IgM or dimeric IgA antibodies induced against Env; such antibodies could block 
mucosal transmission of HIV-1 [54]. 
All attempts to induce 2F5- and 4E10-like antibodies by several immunization strate-
gies have been unsuccessful. Antibodies induced by immunization with recombinant 
antigens presenting the 2F5 and 4E10 epitopes in various protein scaffolds lacked 
broadly neutralizing activity [55-57]. The characteristics of 2F5 and 4E10 suggest that 
successful induction requires antigens with the respective epitopes presented in their 
natural conformation and in an environment that resembles fusion intermediates of 
the HIV-1 infection after receptor binding.  
1.2 Feline foamy virus 
1.2.1 Foamy viruses 
Foamy viruses (FV) belong to the subfamily of Spumaretrovirinae, a genus of Retro-
viridae family. FVs co-evolved with their natural hosts. They are endemic to most 
non-human primates, cat, cattle and horse [58]; man is not a natural host. In the 70s, 
prototype foamy virus (PFV) was isolated which was earlier known as human foamy 









(SFVcpz) suggesting zoonotic transmission from chimpanzee to humans [59-61], alt-
hough human-to-human transmissions remained undetected [59]. FV infections are 
persistent [62] but apathogenic in natural hosts as well as in humans [62]. This fact is 
in stark contrast to the virus’ high cytopathic nature in vitro where infection can end in 
the formation of multinucleated syncytia (cytopathic effect, CPE, Figure 9) followed 
by death of the target cells [63]. The apathogenicity is thought to be a result of inten-
sive evolutionary adoption of virus and its host [58]. 
 
Figure 9: Cytopathic effect (CPE) in 293T cells infected with feline foamy virus (picture kindly 
provided by Michael Mühle of the Robert Koch-Institute) 
Syncytia are framed in red. 
FVs are of great interest for the development of retroviral vector systems and gene 
therapies in view of several reasons. They continuously stimulate the immune system 
[64] because they persist in the host despite the presence of neutralizing antibodies 
and they exhibit a broad host range [65]. In addition to that, the genome of FVs offers 
a high packaging capacity. 9.2 kb of the wild-type SFVcpz-genome with 13.2 kb in 
size can be supplemented by transgenes [66].  
1.2.2 Feline foamy virus genome and Env 
Like in other complex retroviruses, the feline foamy virus (FFV) genome (11.7 kb) en-
codes, in addition to Gag, Env and Pol, accessory and regulatory proteins, as e.g. 
Bel1/2 and Bet (Figure 10). In contrast to other retroviruses, FV Gag lacks a mem-









the formation of virus-like particles (VLPs) [67-70]. Interestingly, FV Env contains 
structural features that allow release of capsid-less subviral particles (SVPs) similar 
in size and shape to VLPs [71].  
The Bel1 gene encodes transactivator (Tas) that binds to the internal promoter (IP) in 
env and the promoter in the 5’LTR. At lower concentrations, Tas binds the IP that has 
higher basal activity and thereby increases its own expression. Accumulation of Tas 
increases binding of the promoter in the 5’LTR which promotes gene expression of 
structural proteins. The positive feedback-loop regulated by Tas thereby allows the 
switch from early accessory to late structural gene expression [72-74]. Activation of 
the IP also induces the gene expression of bet. A splicing event that fuses the bel2 
ORF with the 5’end of the bel1 ORF produces bet. Studies showed that Bet protein 
inhibits APOPEC3 analogously to HIV-1 Vif [75, 76]. 
The envelope glycoprotein (Env) is translated from a single-spliced mRNA. The Env 
precursor molecule (gp130) (Figure 10) consisting of the surface (SU, gp80) and 
transmembrane envelope protein (TM, gp48) is targeted to the rough endoplasmic re-
ticulum by an N-terminal signal peptide.  
 
Figure 10: Feline foamy virus genome organization [77] 
LTR: long terminal repeat with unique 3’ and 5’ region (U3, U5) and repeats (R), gag: group specific 
antigen, pol: polymerase, PR: protease, RT/RH: reverse transcriptase-RNase H domain, IN: integrase, 
env: envelope, Elp: envelope leader peptide, SU: surface protein, TM: transmembrane envelope pro-
tein, IP: internal promoter, bet: between env and LTR. 
Different to orthoretroviruses, the envelope leader peptide (Elp) is not cleaved co-
translationally but remains attached to the full-length precursor molecule and is in-
corporated into virus particles [69, 70, 78]. Along its way through the secretory path-
way, Env is proteolytically cleaved at the furin-cleavage sites to Elp, SU and TM [69, 
70]. Only the SU-TM cleavage is essential for viral infectivity [79-81]. In addition, FV 
Env is N-glycosylated [79] at several sites. In the case of PFV, 14 to 15 potential gly-









for viral infectivity; N8 in gp80 and N13 in gp48 [82]. Similar to HIV Env, FV Env 
forms heterotrimeric spikes on the viral surface [63, 83]. By applying electron micros-
copy of negatively stained PFV particles, it was found that those spikes are densely 
ordered in hexameric rings covering the whole surface of a single virion [83].  
Among most FVs, a KKXX di-lysine motif in the C-terminal cytoplasmic domain of TM 
is conserved [84]. It was shown that in PFV, the KK-motif functions as an endoplas-
mic reticulum retrieval signal (ERRS) because it retains Env in the endoplasmic retic-
ulum from the Golgi network in the absence of other viral proteins [85]. PFV Env 
ERRS mutants show augmented syncytia formation probably due to increased 
transport of Env to the plasma membrane [85, 86].  
Additionally, it was shown that PFV Env is ubiquitinated at five lysine residues locat-
ed in the N-terminal part of its envelope leader peptide. Those ubiquitination sites 
seem to be nonessential for FV particle-release but obviously affect SVP-release in a 
negative way. This was shown by lysine-to-arginine mutations of all five ubiquitination 
sites that resulted in enhanced SVP-release by more than 10-fold [87, 88].  
1.3 Goal of this thesis 
As mentioned above, some HIV-1 infected patients develop neutralizing antibodies 
(nAbs) 2 to 3 years after infection [36-38]. From some infected individuals, even anti-
bodies with broadly neutralizing activity could be isolated. Two of those antibodies 
are 2F5 and 4E10 that bind epitopes in the MPER [41]. Different vaccine strategies 
were tested for induction of 2F5- and 4E10-like antibodies but all attempts remained 
without success.  
It is still unclear which factors are essential for successful induction of nAb. Studies 
suggest that the unusually long CDR3s of 2F5 and 4E10 interact with lipids of the vi-
ral membrane [49, 51], in addition to their respective epitope sequences (Figure 8). 
That characteristic implies that the natural conformation of the 2F5 and 4E10 
epitopes and positioning close to a lipid membrane play a substantial role in antigen-
icity. Besides, the long CDR3s, 2F5 and 4E10 were shown to be highly mutated in 
the frame work regions (FWR) of the variable regions. The FWRs maintain the struc-
tural integrity of the complementarity determining region (CDR) loops and are thus 
critical for broadly neutralizing activities and breadths of bnAbs [89]. As a conse-









91]. This suggests that long affinity maturations are necessary for nAbs to become 
broadly neutralizing.  
In a previous study, sera of animals that were immunized with recombinant feline 
foamy virus (FFV) transmembrane envelope protein (gp48) protein and domestic cat 
sera were screened for antibodies against gp48 [92]. Analysis by use of ELISA and 
immunoblotting showed that FFV positive sera contained antibodies with reactivity 
against gp48. Epitope mapping revealed that the reactivity of antibodies in the im-
munized animals was predominantly against the glycosylated cysteine-rich domain 
(Figure 11) [84, 92]. In contrast, naturally infected cats contained antibodies preferen-
tially recognizing epitopes in the FPPR and MPER (Figure 11). Most of the epitopes 
located in the MPER are arranged similarly to the bipartite motif constituted by the 
2F5 and 4E10 epitopes in HIV-1 gp41, as depicted above in Figure 8.  
 
Figure 11. Antigenic regions in the FFV TM detected by epitope mapping of sera from animals 
that were immunized with the FFV TM and naturally FFV-infected domestic cats [92] 
The schematic of the FFV TM is shown on the top. Indicated are the fusion peptide (FP), the fusion 
peptide proximal region (FPPR), the membrane proximal external region (MPER), the membrane 
spanning domain (MSD), the cysteines (C) and predicted glycosylation sites (Y). Detected epitopes 
are depicted in dark blue boxes (immunized animals) and grey boxes (naturally infected cats). Anti-
bodies induced in naturally infected cats target the FPPR and MPER, whereas antibodies in sera from 
the immunized animals mainly recognized epitopes in the cysteine-rich domain and FPPR.  
According to the mentioned characteristics of FFV Env and the bnAbs 2F5 and 4E10, 
the idea came up to use the FFV Env as a scaffold for the 2F5 and 4E10 epitopes. 
The strategy was to replace the adjacent immunogenic regions in the FFV MPER 









viral particles (SVPs) would turn chimeric FFV/HIV-1 SVPs into ideal immunogens 
because immunogenic reactions against other viral proteins, e.g. FFV Gag [93, 94], 
would thus be excluded. Such an antigen would also have the advantage that the 
2F5 and 4E10 epitopes would be placed in close proximity to a lipid environment just 
like in their natural context.  
This project was based on previous work carried out by my supervisor Michael 
Mühle, in close cooperation with Anne Bleiholder and Martin Löchelt at the German 
Cancer Research Center in Heidelberg. Bleiholder generated hybrid FFV/HIV-1 Env 
expression plasmids that carry the 2F5 and 4E10 epitopes [95]. In her PhD thesis 
she described the characterization of the hybrid FFV/HIV-1 Env proteins by means of 
expression, processing, recognition by mAb 2F5 and mAb 4E10 and their ability to 
promote marker gene transfer (Figure 12A-C) [95]. The MPER1 and MPER2 con-
structs promoted hybrid FFV/HIV-1 Env protein expression and processing as shown 
by detection of gp130, gp48 and a cell lysate-associated form of gp48 (TMCL) (Figure 
12A). In contrast to gp48, TMCL is truncated and  partly glycosylated that also ex-
plains their differential electrophoretic mobility  [95]; processed gp48 runs above, 
while TMCL runs below 50 kDa. Immunoprecipitation of hybrid FFV/HIV-1 MPER1 and 
MPER2 proteins by mAb 2F5 and mAb 4E10 showed that the respective epitopes are 
accessible (Figure 12B). Furthermore, Bleiholder showed that chimeric FFV/HIV-1 
MPER1 and MPER2 proteins did not allow marker gene transfer (Figure 12C). That 
characteristic prevented them for the generation of replication competent FFV/HIV-1 
chimeras for prolonged antigen delivery that could permit antibody affinity maturation. 
However, FFV EnvG2 and hybrid FFV/HIV-1 MPER1 and MPER2 proteins were re-
leased as SVPs (Figure 12D) that turned them into interesting antigens for immuniza-
tion studies. Bleiholder started with the establishment of protocols for the large-scale 
production of SVPs by transiently transfecting HEK293T cells with the pBC EnvG2 
and hybrid pBC FFV/HIV-1 MPER1 and MPER2 expression plasmids. Unfortunately, 
she was able to purify only low yields of SVPs (180-440 ng) from the supernatants 

















Figure 12. Characterization of hybrid FFV/HIV-1 Env and hybrid FFV/PFV MPER Env protein [95] 
A) Immunoblot of HEK293T cell lysates transiently transfected with pBC EnvG2 and hybrid pBC 
FFV/HIV-1 MPER1 and MPER2 expression constructs (see section 4.1) and hybrid FFV/PFV MPER 
expression constructs (irrelevant for this project), as indicated. Detection of antigens was performed 
with goat348 α-TM serum [92]. All recombinant proteins were expressed and processed as shown by 
the detection of gp48 and TM
CL
. MPER1 protein was stronger expressed and cleaved by furin prote-
ase than MPER2 protein. B) Immunoprecipitates of MPER1 and MPER2 proteins from HEK293T cell 
lysates applied to immunoblotting. Immunoprecipitation was with mAb 2F5 or mAb 4E10, as indicated. 
Detection of antigens was performed with goat348 α-TM serum [92]. CL: cell lysate; W4: fourth wash-
ing fraction; IP: immunoprecipitate. The 2F5 and 4E10 epitopes are accessible, since both hybrid 
FFV/HIV-1 Env proteins were immunoprecipitated by both antibodies. C) Titration of marker gene 
transfer particles (MGT) on CRFK cells. EnvG2 served as positive control. Fusion incompetent HIV-1 
MPER1 and MPER2 proteins were unable to mediate MGT. Also shown are functional PFV hybrids (ir-
relevant for this project). D) Immunoblot of subviral particles released by HEK293T cells transiently 
transfected with pBC EnvG2 and hybrid pBC FFV/HIV-1 MPER1 and MPER2 expression constructs 
(see section 4.1), as indicated. Detection of antigens was performed with goat348 α-TM serum [92]. 
The suffixes (A) and (B) indicate different clones. Chimeric FFV/HIV-1 MPER1 and MPER2 SVPs 
were released with reduced efficiency in comparison to EnvG2 SVPs. PFV FPPR1 and MPER SVP-









The goal of this project (Figure 13) was to establish efficient protocols for large-scale 
production of chimeric FFV/HIV-1 MPER SVPs to allow testing of their potential to in-
duce neutralizing antibodies against HIV-1 in rats. This should be done by transduc-
ing target cells with retroviral vectors in order to allow stable expression of Env. For 
this purpose, the recombinant FFV/HIV-1 MPER1 and MPER2 sequences [95] 
should be first subcloned into a retroviral vector. Then protocols for efficient pseudo-
typing with vesicular stomatitis virus protein G (VSV-G) should be established. There-
fore, additives in various concentrations should be screened for increasing virus pro-
duction. In order to generate transduced cells stably producing SVPs, a suitable tar-
get cell line and optimal infection conditions should be found. Native chimeric 
FFV/HIV-1 SVP antigens should then be tested for the accessibility of the 2F5 and 
4E10 epitopes for the respective antibodies. Electron microscopy should be applied 
to confirm release of SVPs. Finally, different serum-free expression media should be 
tested for optimal large-scale production and purification of SVP antigens.  
 









2 Materials   
2.1 Equipment 
Avanti™ J-20XP, centrifuge 
 
Beckman Coulter 
Beaker glasses 10 ml, 50 ml, 100 ml, 500 ml Schott Duran 










Eppendorf centrifuge 5415D 
 
Eppendorf 








10 µl, 20 µl, 100 µl, 200 µl, 1000 µl Eppendorf 
Eppendorf Research®, 
multi-channel 
30-300 µl Eppendorf 
Erlenmeyer flasks 50 ml, 100 ml, 500 ml, 1 l, 5 l Schott Duran 
FACSCalibur™  BD Biosciences 
Finnpipette® 50-300 µl Thermo Scientific 
Fluorescence microscope, Axiovert 100M 
 
Zeiss 
Glas flasks 50 ml, 100 ml, 500 ml, 1 l Schott Duran 
Glas pipettes  5 ml, 10 ml Hirschmann 
Guava PCA analysis system  Millipore 
Heraeus Multifuge 1S-R Centrifuge 
 
Thermo Scientific 












Multiskan™ GO UV/Vis microplate spectrophotometer 
 
Thermo Scientific 
Mx30005P™, Real-time PCR-cycler 
 
Stratagene 















PIPETMAN® Classic P2, P10, P20, P100, P200, P1000 Gilson 
Pipette boy accu-jet® pro 
 
BrandTech Scientific 
SDS electrophoresis chamber 
 
CBS Scientific 
Shaker, GFL® 3016 
 
GFL 
SW32, rotor for ultracentrifuge 
 
Beckman Coulter 
SW41, rotor for ultracentrifuge 
 
Beckman Coulter 
Thermomixer comfort  
 
Eppendorf 
Transilluminator system and software 
 
Biorad 
Type19, rotor for ultracentrifuge 
 
Beckman Coulter 
















Cell culture flasks T-25, T-75, T-160 Techno Plastic Products 
Cell scraper  
 
Techno Plastic Products 
Centrifuge tubes 14 x 89 mm Beckman Coulter 
Centrifuge tubes 25 x 89 mm Beckman Coulter 
Corning® HYPERFlask® 
Cell Culture Vessels  
Corning Life Sciences 
Cryotube™ vials 1.5 ml, 1.8 ml Nunc™ 
Eppendorf tubes 1,5 ml, 2 ml Eppendorf 
Falcon tubes 15 ml, 50 ml Techno Plastic Products 
Nitrocellulose membrane 0.2 µm GE Healthcare 
Plastic pipettes 1 ml, 2 ml, 5 ml, 10 ml, 25 ml Techno Plastic Products 
Sterile filter  Stericup-Filter 0.22 µm; 0.45 µm Millipore 
Tissue culture dishes 10 cm, 15 cm Techno Plastic Products 
Tissue culture plates 6-, 12-, 24-, 48- or 96-well Techno Plastic Products 
2.3 Chemicals 
2-mercaptoethanol Carl Roth 
Acrylamide Carl Roth 
Adenosin triphosphate (ATP) Thermo Scientific 
Agarose Carl Roth 
Ammoniumpersulfat (APS) Carl Roth 
Ampicillin Carl Roth 
Benzonase Novagen 
Big Dye ABI 
Blasticidin S hydrochloride Sigma-Aldrich 
BSA New England Biolabs 
dNTPs Thermo Scientific 
ECL (Enhanced chemiluminescence) Thermo Scientific 
EDTA Serva 
Ethanol Carl Roth 
Ethidium bromide Sigma-Aldrich 
Fetal Calf Serum Biochrom 
Geniticinsulfat (G418)-Lösung Carl Roth 
Glycerin Carl Roth 
Glycin Carl Roth 
Guava® ViaCount® reagent Millipore 
HEPES Biochrom 
Isopropanol Carl Roth 
L-Glutamine Biochrom 
Methanol Carl Roth 
Milk powder, low fat Carl Roth 
Nuclease-free water QUIAGEN 
Orange Loading Dye Thermo Scientific 
Penicillin/Streptomycin Biochrom 
Polybrene Sigma-Aldrich 









Polyethylenimine (PEI) Sigma-Aldrich 
Protease inhibitor Roche 
Rabbit serum Sigma-Aldrich 
Sodium butyrate Sigma-Aldrich 
Sodium chloride Carl Roth 
Sodium dodecyl sulfate (SDS) Carl Roth 
Sodium hydroxide Carl Roth 
Tetramethylethylenediamine (TEMED) Carl Roth 
Tricine Carl Roth 
Tris Carl Roth 
Tris-HCl Carl Roth 
Trypsin Invitrogen 
Tween 20 Carl Roth 
Valproic acid Sigma-Aldrich 
Protein G Seqharose™ 4 Fast Flow GE Healthcare 
2.4 Kits 
DNeasy® Blood & Tissue Kit (250) QIAGEN 
In-Fusion® HD Cloning Plus Clontech 
Invisorb® Spin DNA Extraction Kit (250)  Invitek 
Invisorb® Spin Plasmid Mini Kit Two (250)  Invitek 
Nucleobond® AX  Macherey-Nagel 
One Step RT-PCR Kit QIAGEN 
Pierce™ BCA Protein Assay Kit Thermo Scientific 
Plasmid Midi/MaxiKit QIAGEN 
RNeasy® Mini Kit (250) QIAGEN 
2.5 Buffers and solutions 
2.5.1 SDS-PAGE and immunoblotting 
10x Anode buffer 242 g/l Tris, pH 8.9 
10x Cathode buffer 121 g/l Tris, 179 g/l tricin, 10 g/l SDS, pH 8.25 
Transfer buffer 48 mM Tris, 35 mM glycin, 20 % methanol, 0.03 % SDS 
Stripping buffer 
92 % [v/v] H2O, 6.25 % [v/v] 1 M Tris-HCl pH 6.7, 2 % [w/v] 
SDS, 0.7 % [v/v] 2-mercaptoethanol 
SDS-Gel buffer 36.3 % [w/v] Tris, 1.5 % [v/v] 20 % SDS, pH 8.4 
Blocking solution 3 % [w/v] low-fat milk powder, 1 % rabbit serum, PBS-Tween 20 
Washing solution, PBS-
Tween 20 
0.05 % [v/v] Tween 20 
SDS-sample buffer 
50 mM Tris-HCl, 12 % glycerol, 4 % SDS, 5 % 2-









2.5.2 Agarose gel-electrophoresis 
Tris-acetate-EDTA (TAE, 50x) 2 M Tris, 50 mM EDTA, 1 M acetate 
2.5.3 Lysis buffers 
SDS-lysis buffer 1 % SDS, 1x PBS 
RIPA-buffer 
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 % NP-40, 0.5 % Sodi-
umdeoxycholat, 0.1 % SDS, 5 mM EDTA, 1x Protease Inhibitor 
Cocktail 
2.5.4 Other buffers 
10x Fast Digest Buffer Green Thermo Scientific 
Buffer HS2, for HotStart Taq DNA-Polymerase Sengenetic 
Buffer C, for AccuProof DNA-Polymerase Sengenetic 
Phusion® GC Reaction Buffer New England BioLabs 
6x Orange Loading Dye Thermo Scientific 
2.6 Protein and DNA ladders 
Gene Ruler 1 kb DNA Ladder, Ready-to-use Thermo Scientific 
O'Gene Ruler™  DNA Ladder Mix, Ready-to-use Thermo Scientific 
peqGOLD Protein Marker IV PEQLAB 
2.7 Enzymes 
2.7.1 Restriction enzymes 
All restriction enzymes were purchased from Thermo Scientific as Fast Digest-
enzymes. 




















AccuProof DNA Polymerase Sengenetic 
Clone Amp HiFi PCR Premix Clontech 
Hot Start Taq DNA-Polymerase Sengenetic 
Pfu DNA-Polymerase Thermo Scientific 
Phusion® Hot Start HD flex New England BioLabs 
AmpliTaq Gold® with GeneAmp® Roche 
2.7.3 Other enzymes 
In-Fusion® HD Enzyme Premix Clontech 
Klenow-Fragment Thermo Scientific 
Shrimp alkaline phosphatase (SAP) Thermo Scientific 
T4 DNA-Ligase Thermo Scientific 
T4 Polynucleotide kinase (PNK) Thermo Scientific 
Benzonase Novagen 
2.8 Primers 
The primers were designed with gene maps and synthesized by Eurofins MWG Op-
eron. 
Primer Sequence (5'-3') 
FFV EnvG2 fwd ATA GCG GCC GCA TGG AAC AAG AAC ATG TGA TG 
FFV EnvG2 rev 
TAT GTT TAA ACC TAG TGA TGG TGA TGG TGA TGT 
TGG TCC TTC TTC 
FFV TMH fwd AGG CAT TCA TGC CTT TTG GAT TCT 
FFV TMH rev CTT CAA AAT ACC CGG AAG AAG GAC CAA 
TM seq fwd TGG AAA TGG AAC TGG TTC AGA CTG C 
FFV Int sequencing primer rev GTC ACC TTG TAA GGA ATG CAG G 
FFV SU rev TGA ATT AGT CAC CTG CCA GCT TAA 
FFV FP rev GCC TAA GCC TGC CTC TTG TAT CCT TCT TA 
Elp1 fwd 
TGG AAT GCT CAC CGA CAA CTA CAG CGA CTT 
CAG TCG ACT CAT 
Elp1 rev 
TTC CAT CCA TTC CCG CAG GGT CAT CAC ATG TTC 
TTG TTC CAT 
Elp2 fwd 
CCA GAG CGG GTA CCT TTG CGA ATG AGG ATG 
CGA TAT AGA TGT 
Elp2 rev 
TAC TAA AGG AAT ATC CTC AGG TAT GTC AAC ATG 
CAA CTC AGG 
PRE fwd TTC TGG GAC TTT CGC TTT CC 
PRE2 rev CAT GGA AAG GAC GTC AGC TT 
FFV Env Fusion1 
CAC TTA CAG GCG GCC GCG CCG CCA CCA TGG 
AAC AAG AAC ATG TGA 
FFV Env Fusion2 
TAA GAT GCT CGA ATT CCT AGT GAT GGT GAT 









2.9 Probe for real-time PCR 
PRE2 Probe fwd AAC TCA TCG CCG CCT GCC TTG 
2.10 Plasmids 
Plasmids Description Reference/vendor 
pLenti-GFP 
Modified version of the retroviral vector 
pLenti CMV GFP Puro (658-5). 
Addgene, Plasmid 17448 
pMDLg/pRRE 
Lentiviral vector carrying the HIV-1 structural 
genes gag and pol. 
Addgene, Plasmid 12251 
pRSV-Rev 
Lentiviral packaging plasmid encoding HIV-1 
Rev protein. 
Addgene, Plasmid 12253 
pMD2.G 
Envelope plasmid coding for the vesicular 
stomatitis virus protein G (VSV-G). 
Addgene, Plasmid 12259 
MP71-GPRE 
MP71-GPRE naturally contains a GFP and 
has the 856-bp woodchuck hepatitis virus 
post-transcriptional regulatory element 
(PRE) (GPRE). It is a retroviral vector with a 
murine myelo-proliferative sarcoma virus 
(MPSV) LTR and an improved leader se-
quence derived from murine embryonic stem 





FFV EnvG2, FFV EnvG2xHIV-1 MPER1/2 
sequences in pBC12 backbone. For details 
see section 4.1. 
[95] 
pCF7 
Codes for an infectious molecular clone of 
feline foamy virus. 
[97] 
pEGFP-N3 
Encodes an enhanced variant of GFP that is 
flanked by Kozak consensus translation initi-
ation sites for increased expression. A multi-
ple cloning site is incorporated between an 















2.11 Antibodies and antisera 
2.11.1 Primary antibodies 
Antibody Dilution Reference/vendor 
mAb 4E10 1:20000 
The following reagent was obtained through the NIH 
AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
HIV-1 gp41 Monoclonal Antibody (4E10) from Dr. 
Hermann Katinger. [98] 
mAb 2F5 1:20000 
The following reagent was obtained through the NIH 
AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
HIV-1 gp41 Monoclonal Antibody (2F5) from Dr. Her-
mann Katinger. [99-101] 
mouse α-GFP HRP 1:1000 Santa Cruz,  SC9996 
mouse α-β-actin 1:5000 Sigma-Aldrich 
2.11.2 Antisera 
Antiserum Dilution Reference 
goat 348 α-FFV TM 1:1000 [92] 
rat 321-3 α-FFV TM 1:1500 [92] 
2.11.3 Secondary antibodies 
Antibody Dilution Vendor 
poly rabbit α-mouse HRP 1:3000 Dako 
poly rabbit α-human HRP 1:3000 Dako 
poly rabbit α-goat HRP 1:3000 Dako 
2.12 Media 
2.12.1 Media for bacteria 
Lysogeny broth (LB) 10 g/L tryptone, 5 g/L yeast extract, 100 mM NaCl, pH 7.0 











2.12.2 Media for cell cultures 
Medium Vendor/supplements 
Dulbecco's Modified Eagle Medium (DMEM) 
GE Healthcare 
Supplemented before use with: 10 % [v/v] 
FCS, 2 mM L-glutamine, 10 mM HEPES, 5 
mM penicillin/streptomycin 
Dulbecco's Modified Eagle Medium (DMEM), 
High Glucose (4.5 g/l) 
GE Healthcare 
Supplemented before use with: 10 % [v/v] 
FCS, 2 mM L-glutamine, 10 mM HEPES, 5 
mM penicillin/streptomycin 
EX-CELL® VPRO, Serum-Free Medium Sigma-Aldrich  
FreeStyle™ 293 Expression Medium Life Technologies 
HyClone™ SFM4HEK293™ Medium Thermo Scientific 
Roswell Park Memorial Institute medium 
(RPMI) 
GE Healthcare 
Supplemented with: 10 % [v/v] FCS, 2 mM L-
glutamine, 10 mM HEPES, 5 mM penicil-
lin/streptomycin 
2.12.3 Freezing media for eukaryotic cells 
Cell line Freezing medium 
Platinum-GP 70 % DMEM, 20 % FCS, 10 % DMSO 
C8166-45 RPMI with 83 % L-glutamine, 10 % FCS, 7 % DMSO 
CRFK 10 % DMSO in FCS 
FreeStyle™ 293-F Cells FreeStyle™ 293 Expression Medium with 10 % DMSO 
HEK293T 70 % DMEM, 20 % FCS, 10 % DMSO 
2.13 Prokaryotic strains 





+) supE44 thi-1 
recA1 gyrA96 relA1 lac F′[proA+B+ la-
cIqZΔM15::Tn10] (TetR) 
Novagen 
Stellar™ Competent Cells 
F–, endA1, supE44, thi-1, recA1, relA1, gy-
rA96, phoA, Φ80d lacZΔ M15, Δ (lacZYA - 












2.14 Eukaryotic strains 
Cell line Specification Vendor 
C8166-45 
C8166 cells are human umbilical cord 
lymphocytes that contain the poorly 
infectious HTLV-1CR virus; increased 
production of HTLV-1. Morphology is 
T-lymphoid. C8166 cells are cultured 
in suspension. 
The following reagent was 
obtained through the NIH 
AIDS Reagent Program, 
Division of AIDS, NIAID, 
NIH: C8166-45 (Cat# 404) 
from Dr. Robert Gallo. 
CRFK cells 
The CRFK cells are feline kidney 
cells with an epithelial morphology.  
ATCC 
FreeStyle™ 293-F Cells 
The 293F cell line that is derived from 
the 293 cell line is adapted to be 
grown as suspension cultures in se-
rum-free expression media (e.g., 




The human kidney cell-derived 
HEK293T cell line is adenovirus im-
mortalized and stably expresses 
large SV40 T antigen. HEK293T cells 
are used for transient transfection.  
ATCC 
Platinum-GP (Plat-GP) 
The Plat-GP is a 293T cell line-
derived retrovirus packaging cell line 
which stably expresses retroviral 
structure proteins (gag and pol) under 
blasticidin selection.  
Cell Biolabs, Inc. 
2.15 Software 
ClustalW2, EMBL-EBI Multiple sequence alignment 
DNASTAR Lasergene SeqBuilder Generation of sequence maps  
DNASTAR Lasergene SeqMan Pro Analysis of sequencing data 
Expasy translate tool 
Translation of nucleotide se-
quences into amino acid se-
quences 
Oligo Analyzer, Integrated DNA Technologies 











3.1 Molecular biological methods 
3.1.1 PCR for subcloning 
The DNA sequences of FFV EnvG2, FFV EnvG2 x MPER1 and FFV EnvG2 x 
MPER2 were PCR-amplified (Table 1) with the pBC EnvG2, MPER1 x pBC EnvG2 
and MPER2 x pBC EnvG2 expression plasmids [95] as templates. In order to allow 
subcloning into MP71-GPRE by homologous recombination, the primers FFV Env 
Fusion1 and FFV Env Fusion2 were designed to add 15 bp extensions 5’ and 3’ ho-
mologous to vector regions confining the GFP gene in MP71-GPRE. In addition, the 
primer FFV Fusion2 added a Histidine-Tag-encoding sequence 3’ of the amplicon.  
 








95 °C, 5 min 
 
 
FFV Env Fusion1 7.5 pmol 
 
98 °C, 30 sec, denaturation 
30x FFV Env Fusion2 7.5 pmol 
 
55 °C, 15 sec, annealing 
Template DNA   100 ng 
 
72 °C, 20 sec, elongation 
Nuclease-free H2O ad 25 µl 
 
72 °C, 5 min 
 
3.1.2 Mutagenesis-PCR 
The mutations K10R, K20R, K24R, K45R and K48R were incorporated into the FFV en-
velope leader peptide (Elp) of gp48 (Figure 35) by performing two rounds of PCR 
(Table 2) and self-circularization. pBC EnvG2, MPER1 x pBC EnvG2 and MPER2 x 
pBC EnvG2 [95] served as templates. Before PCR, the primers Elp1 fwd, Elp1 rev, 
Elp2 fwd and Elp2 rev carrying the desired mutations were phosphorylated for 1 hour 














 5x Phusion HF 25 µl 
 
98 °C, 30 sec 
Primer fwd-P 2.5 µl (10 pmol/µl) 
 
98 °C, 10 sec, denaturation 
35x Primer rev-P 2.5 µl (10 pmol/µl) 
 
55 °C, 15 sec, annealing 
dNTP 1 µl (10 mM) 
 
72 °C, 3 min, elongation 
Phusion® Hot Start HD flex 0.5 µl 
 
72 °C, 5 min 
 Template DNA  10 ng 
   Nuclease-free H2O ad 50 µl 
   
 
Table 3: Mixture for primer phosphorylation 
Reagent Volume/amount 
Primer (100 pmol/µl) 0.9 µl 
10x T4 PNK buffer A 0.9 µl 
10 mM ATP 0.9 µl 
T4 PNK 0.8 µl 
Nuclease-free H2O 5.5 µl 
3.1.3 Colony PCR 
Colony PCR was used to screen transformed bacteria for positive clones. For this 
purpose, single colonies were directly picked from an agar plate with a pipette tip. Be-
fore mixing with the PCR reaction mix (Table 4), the single clones were put onto a 
back-up plate.  
 




 10 x buffer 1.5 µl 
 
94 °C, 10 min 
MgCl2 1.2 µl 
 
95 °C, 30 sec, denaturation 
25x dNTPs 0.3 µl (10 mM) 
 
52 °C, 30 sec, annealing 
5`-primer 0.3 µl (10 pmol/µl) 
 
72 °C, 1 min 20 sec, elongation 
3`-primer 0.3 µl (10 pmol/µl) 
 
72 °C, 5 min 
 
Hot Start Taq DNA-
Polymerase 
0.2 µl 
   
Template  single clone 
   
Nuclease-free H2O ad 15 µl 











3.1.4 Reverse transcription-PCR (RT-PCR) 
After isolation of RNA from transfected cells, RNA transcripts were first reverse tran-
scribed to cDNA and subsequently amplified by RT-PCR (Table 5) using the 
OneStep RT-PCR kit from QIAGEN. Amplified cDNA was separated by 1 % agarose 
gel-electrophoresis. Finally, desired amplicons were extracted from gels and se-
quenced.  
3.1.5 Real-time PCR 
FFV EnvG2 or FFV/HIV-1 MPER1 or MPER2 virus titers were determined using real-
time PCR (Table 6, see section 4.4.1). In contrast to primer-to-template hybridization 
that is assisted by polymerase, probe-to-template hybridization lacks this support. In 
order to increase probe-to-template hybridization, elongation-temperature and an-
nealing-temperature were matched [102]. All PCR-runs were carried out with a 
Mx3005™ Real-time PCR cycler from Stratagene.  
 





5x QIAGEN OneStep RT-PCR Buffer 5 µl 
 
50 °C, 30 min, reverse transcription 
dNTP Mix 2.0 µl 
 
95 °C, 15 min, initial PCR activation  
Primer fwd 0.3 µM 
 
94 °C, 1 min, denaturation 
50x Primer rev 0.3 µM 
 
50 °C, 1 min, annealing 
QIAGEN OneStep RT-PCR Enzyme Mix 1 µl 
 
72 °C, 1 min, extension 
Isolated RNA 1 pg - 2 µg 
 
72 °C, 10 min, final extension 
 
RNase-free H2O ad 25 µl 
   
Table 6: PCR mix for real-time PCR   
Reagent Volume/amount 
 
Cycler conditions  
10 x buffer 2.5 µl 
 
95 °C, 10 min 
 
50x 
MgCl2 25 mM 
 
95 °C, 30 sec, denaturation 
dNTPs 0.5 µl (10 mM) 
 
58 °C, 1 min, annealing and 
elongation 5`-primer, PRE fwd 0.5 µl (10 pmol/µl) 
 
3`-primer, PRE 2 rev 0.5 µl (10 pmol/µl) 
 
AmpliTaq Gold® with GeneAmp® 0.25 µl 
   
 
Genomic DNA 100 ng 
   
 











3.1.6 Subcloning with the In-Fusion® HD Protocol from Clontech 
The In-Fusion® system is for subcloning DNA sequences into target vectors based 
on homologous recombination (Figure 14) [103]. In order to allow homologous re-
combination with MP71-GPRE, PCR-amplification of the FFV EnvG2, FFV EnvG2 x 
MPER1 and FFV EnvG2 x MPER2 sequences was performed with primers that add-
ed 5’ and 3’ 15 bp extensions homologous to the MP71 regions flanking the eGFP 
sequence (see section 3.1.1.). The amplicons were introduced into MP71 in a single 
reaction (Table 7) which was incubated at 50 °C for 15 min. Subsequently, NovaBlue 
Giga Singles were transformed with the reaction mixtures. The following day, single 
colonies were picked for colony-PCR.  
 
Table 7: In-Fusion® HD mix 
Reagent Volume/amount 
PCR-product 50-100 ng 
linearized MP71 50-100 ng 
5x Fusion Enzyme Premix 2 µl 











Figure 14. In-Fusion HD work-flow overview [103] 
The EnvG2, EnvG2 x MPER1 and EnvG2 x MPER2 sequences were PCR-amplified using the primers 
FFV Env Fusion1 and FFV Env Fusion2 that added 5’ and 3’ 15 bp extensions homologous to linear-
ized MP71. After separation with 1 % agarose gel-electrophoresis, the desired amplicons were eluted 
from gel pieces by spin-column purification. In a single reaction, the sequences were introduced into 
MP71 by homologous recombination. Afterwards, NovaBlue Giga Singles were transformed with the 









3.1.7 Ligation and self-circularization 
T4 DNA ligase enzyme was used for self-circularization (Table 8) of linear plasmids 
that were amplified by mutagenesis-PCR. Reaction mixtures were incubated at 37 °C 
for 1 hour, before transformation into NovaBlue GigaSingles™ Competent Cells. 
 
Table 8: Self-circularization of a linear  vector amplicon 
Reagent Volume/amount 
Linear plasmid DNA  10-20 ng 
10x ligase buffer 2 µl 
T4 ligase (5 U/µl) 1 µl 
Nuclease-free H2O ad 20 µl 
3.1.8 Restriction digestion 
Restriction digestion of DNA was either performed for analytical or subcloning pur-
poses. All restriction enzymes were purchased as FastDigest enzymes from Thermo 
Scientific with 100 % activity in the universal FastDigest Buffer and FastDigest Buffer 
Green. Therefore, double-digestions in single reactions are possible, regardless of 
the enzymes used. For analytical control digests, FastDigest Buffer Green was ap-
plied because it allows direct loading of reaction mixtures onto agarose gels. Accord-
ing to the manufacturer, FastDigest enzymes are optimized to digest 1 µg DNA in 5 - 
15 min. For cloning purposes, reactions were incubated up to 1 hour at 37 °C to as-
sure complete digestion.  
3.1.9 Isolation of plasmid DNA from E.coli 
For isolation of plasmid DNA from E.coli, the Invisorb® Spin Plasmid Mini Kit Two 
(250), Plasmid Midi/MaxiKit or Nucleobond® AX was used. The procedure of isola-
tion was performed according to the protocols of the manufacturers.  
3.1.10 Isolation of genomic DNA from eukaryotic cells 
For isolation of genomic DNA from transduced cells, the DNeasy® Blood & Tissue Kit 
(250) from QIAGEN was used. The procedure of isolation was performed according 
to the protocols of the manufacturer. Genomic DNA was subjected to real time-PCR 









3.1.11 Isolation of RNA from eukaryotic cells 
For isolation of RNA from transfected cells, the RNeasy® Mini Kit (250) from QI-
AGEN was used. The procedure of isolation was performed according to the protocol 
of the manufacturer. Isolated RNA was subjected to reverse transcription-PCR.  
3.1.12 Determination of DNA concentrations 
Concentrations of purified DNA solutions were spectrometrically determined at 260 
nm with a NanoDrop® device from peqLab.  
3.1.13 Sequencing and analysis of cloned plasmid constructs 
Sequencing of cloned plasmid constructs was performed according to Sanger. In Ta-
ble 9 the amounts for a single sequencing PCR mix are shown. After PCR, reaction 
mixtures were handed over to the sequencing laboratory of the Robert Koch-Institute 
for compilation of the sequencing data. The obtained data were evaluated with the 
DNASTAR Lasergene SeqMan Pro software.  
 
Table 9: PCR mix for sequencing 
Reagent Volume/amount 
Primer 0.5 µl 
Big Dye 3.1 2 µl 
5x Buffer 1 µl 
Template DNA  150-300 µl 
Nuclease-free H2O ad 10 µl 
3.1.14 Agarose gel-electrophoresis 
DNA fragments were separated according to their lengths in 1 % agarose gels. Aga-
rose was dissolved in 1x TAE buffer by boiling in a microwave. After cooling the aga-
rose solution to a moderate temperature, 0.001 % (v/v) ethidium bromide was added 
to allow subsequent visualization of DNA fragments by exposure to UV light. Mixtures 
were poured into an electrophoresis chamber and incubated until full polymerization. 
Gels were placed in a gel apparatus containing TAE buffer. Before loading, DNA 
samples were mixed with 6x Orange Loading Dye. Separations were performed at 
130 V. Gels were visualized and documented with a transilluminator system and 









3.1.15 Extraction and purification of DNA fragments from agarose gels 
After gel-electrophoresis, DNA bands with the intended size were excised from gels 
under UV-exposure for visualization. DNA was extracted and purified from the gel 
slices using the Invisorb® Spin DNA Extraction Kit (250). The procedure of DNA puri-
fication was performed according to the protocol of the manufacturer.  
3.1.16 Transformation of competent bacteria 
For plasmid amplification, DNA was delivered into competent NovaBlue Gi-
gaSingles™ Competent Cells by heat shock. Competent bacteria kept at -80 °C were 
thawed on ice. 1 - 10 ng plasmid DNA or 10 µl self-circularization reaction mixture 
were added to 50 µl of bacterial suspension. After incubation on ice for 10 min, bac-
teria were heat shocked at 42 °C for 30 sec. and further incubated on ice for 2 min. 
Then 250 µl pre-warmed S.O.C.-medium were added. Before plating on agar-plates 
supplemented with ampicillin for positive selection, transformed bacteria were incu-
bated shaking at 37 °C for 10 min.  
3.1.17 Preparation of glycerol stocks of single clones for long-term storage 
Single colonies of positive clones were stored as glycerol stocks. For this purpose, 
900 µl of bacterial overnight-culture were mixed with 600 µl of 50 % sterile-filtered 
glycerol. Tubes containing bacterial suspensions were immediately put into liquid ni-
trogen. Finally, the stocks were stored at -80 °C. 
3.2 Cell cultural methods 
3.2.1 Thawing and establishing of eukaryotic cells 
Frozen cells in cryo-tubes stored in liquid nitrogen were thawed in a water bath. 
When only a small piece of ice was visible, cell suspensions were immediately trans-
ferred into fresh culture medium in order to mitigate toxic effects of the DMSO-
supplemented freezing medium. DMSO was completely removed by pelleting cells 
and discarding the supernatant. Cells were resuspended in fresh culture medium and 









3.2.2 Subculturing of cells 
About every second to third day, confluent adherent cell cultures (HEK293T, Plat-GP) 
or suspension cultures (293F, C8166) with a density of 1 x 106 - 3 x 106 cells/ml were 
split at ratios of 1:2 to 1:10, depending on the confluency or cell density of cultures. 
Suspension cultures were split by resuspending pelleted cells in an appropriate 
amount of culture medium and diluting the cell suspensions. Adherent cell cultures 
first had to be detached with trypsin. For this purpose, culture medium was removed 
and cells were washed with 10 - 15 ml 1x PBS. Subsequently, 2 - 5 ml trypsin/EDTA 
solution was added. Trypsin digest was incubated at 37 °C for up to 5 min until cells 
were floating. Cells were resuspended in culture medium and split at a desired ratio.  
3.2.3 Determination of cell numbers and viabilities 
In order to define cell numbers and viabilities of cell suspensions, the Guava® 
ViaCount® assay from Millipore was used. For this purpose cell suspensions were 
prepared as described above. 20 µl cell suspension with unknown cell density were 
mixed with 180 µl Guava® ViaCount® reagent (1:10-dilution) in a 1.5 ml reaction 
tube. Subsequently, the tube was immediately placed in the retainer of the Guava 
PCA analysis system for analysis with the Guava ViaCount application of the Cyto-
Soft software. The Guava® ViaCount® assay differs between viable and dead cells. 
The Guava® ViaCount® reagent is composed of two different fluorescent dyes. Nu-
cleated cells are stained with a membrane-permeable DNA-binding dye, while dead 
cells are stained with a dye that can only penetrate membranes with impaired integri-
ty. The fluorescence signal emitted from the DNA-binding dye is detected by the pho-
tomultiplier 2 (PM2) of the Guava PCA analysis system. The dead cell stain is de-
tected by PM1. Each signal leads to a counted event if the corresponding forward 
scattered signal (FSC) intensity is appropriate for a nucleated cell [104]. Before data 
acquisition, the system settings were adjusted with the Guava ViaCount application. 
If necessary, the voltage settings were changed so that live and dead populations 
could be distinguished on the plots (PM1/FSC, PM2/PM1). The FSC threshold was 
moved to exclude cell debris from detected cells and the PM2 threshold was shifted 
to separate the live and dead cell populations. After data acquisition of standardly 
1000 events, the CytoSoft software calculated the viability and the cell density of the 









3.2.4 Freezing cells 
For freezing cells, 2 ml of a cell suspension (up to 1 x 107 cells/ml) in freezing medi-
um were transferred into cryo-tubes. Then, tubes were put into a cryo-container 
which allows slow cooling of cells to -80 °C at a rate of -1 °C/min. The following day, 
tubes were transferred into liquid nitrogen for long-term storage. 
3.2.5 Transfection of cells 
Cells were transiently transfected using polyethylenimine (PEI). The day before trans-
fection, adherent cells were seeded to 30 % confluency. In order to find optimal trans-
fection conditions to produce virus, 0.5 µg, 1 µg or 2 µg plasmid DNA and various 
DNA/PEI-ratios were tested in parallel, as described in detail in section 4.2.1.  
For pseudotyping of MP71 vectors with vesicular stomatitis virus protein G (VSV-G), 
the packaging cell line Platinum-GP was co-transfected with MP71 expression plas-
mid and VSV-G-encoding vector; the relative amount was 2:1.  
VSV-G pseudotyped pLenti vectors were produced by co-transfection of HEK293T 
cells with pLenti expression plasmid and Gag/Pol-, Rev- and VSV-G-encoding plas-
mids; the relative amount was 5:3.75:1.5:1.  
Transfection mixtures were vigorously vortexed and evenly distributed onto cell cul-
tures after incubation at room temperature for 15 min. Culture media were replaced 5 
hours later. After additional 24 hours, culture media were supplemented with different 
amounts of histone deacetylase-inhibitors, valproic acid or Na-butyrate, in order to 
test their influence on transgene expression or virus production (see section 4.2.2).   
3.2.6 Transduction of cells 
The day before transduction, adherent cells were seeded to 20 - 30 % confluency. 
Suspension cultures were diluted to a density of 5 x 105 cells/ml at the time of trans-
duction. Concentrated virus was added to cultures. Different conditions for enhance-
ment of infection were tested by supplementation of media with 8 µg/µl polybrene, by 
centrifugation of infected cultures at 1000 g at 30 °C for 1 hour or by combination of 
both where polybrene was added before centrifugation (see section 4.3). Media were 









3.2.7 Concentration of virus particles 
Cell culture supernatants were harvested 48 and 72 hours after transfection. After 
pooling both supernatants, they were centrifuged at 4000 rpm for 5 min and filtered 
through a 0.45 µm filter in order to remove residual cells and cell material. Virus was 
concentrated either by polyethylene glycol precipitation according to the protocol of 
Tiscornia et al. [105] or pelleted by centrifugation with an Avanti™ J-20XP centrifuge 
at 75500 g at 4 °C for 2 hours. Subsequently, culture media were quickly decanted. 
Tubes were incubated upside down on a filter paper to allow draining of residual liq-
uid. Dried virus pellets were resuspended in PBS as 50 - 100x concentrates of the 
initial cell culture supernatant. Viral concentrates were used for infection or stored at -
80 °C. 
3.2.8 Concentration of cell culture supernatants containing subviral particles 
Cell culture supernatants supposed to contain subviral particles (SVPs) were har-
vested 48 hours after transduction. Supernatants were centrifuged at 4000 rpm for 5 
min and filtered through a 0.45 µm filter in order to remove residual cells and cell ma-
terial. Cell-free supernatants were stored at 4 °C or applied to ultracentrifugation on a 
20 % sucrose/1x PBS cushion in a SW41, SW32 or Type19 rotors, depending on the 
volume of the supernatant. The volume of 20 % sucrose/1x PBS was one-fifth of the 
tube’s maximum liquid capacity. Centrifugation was performed at 28000 rpm (SW41, 
SW32) or 19000 (Type19) for 2 or 5 hours, respectively. Subsequently, culture media 
and sucrose cushions were decanted. Tubes were incubated upside down on a filter 
paper to allow draining of residual liquid. Dried pellets were resuspended in either 1x 
PBS containing protease inhibitor or sample buffer as 200 - 1000x concentrates of 
the initial cell culture supernatant. Concentrates were directly applied to SDS-PAGE, 
electron microscopy, immunoprecipitation or stored at 4 °C.  
3.2.9 Large-scale production of subviral particles 
Transduced cell cultures were first expanded into four T-160 flasks before large-scale 
production of subviral particles (SVPs). For further experiments, Corning® HYPER-
Flask® Cell Culture Vessels were applied to avoid space constraints in the incubator 
and allow easy handling of large amounts of cells. Therefore, transduced cell cultures 
were pooled and 1 x 107 cells were transferred into 500 ml of DMEM with high glu-









After 48 hours, cell culture supernatants were harvested and stored at 4 °C or con-
centrated. Cells were washed with 100 ml of 1xPBS and detached by adding 50 ml 
trypsin solution. Before retrieval from HYPERFlasks®, 50 ml of fresh culture medium 
were added. 1 x 107 cells were transferred into 500 ml fresh DMEM HG to start an-
other round of large-scale production of SVPs.  
3.3 Biochemical and immunological methods 
3.3.1 Preparation of cell lysates 
Cell culture media were removed from transiently transfected HEK293T or Plat-GP 
cell cultures. Cells were washed once with 1x PBS and scraped from culture dishes. 
Cell suspensions were transferred to 1.5 ml reaction tubes and pelleted by centrifu-
gation. Supernatants were subsequently discarded. Suspension cells were directly 
pelleted in appropriate tubes to separate them from culture media. In order to de-
grade genomic DNA and other nucleic acids during lysis, 1 µl Benzoase was added 
to the cell pellets and incubated at 37 °C for 5 - 10 min. Cells were lysed with 100 - 
250 µl lysis buffer at room temperature for 5 - 10 min. Lysates were put on ice before 
proceeding with the Pierce™ BCA Protein Assay or stored at -20 °C.  
3.3.2 Determination of protein concentrations 
In order to determine protein concentrations of cell lysates, the Pierce™ BCA Protein 
Assay was applied. In 96-well plates, 4 µl sample per well were mixed with 200 µl of 
a 1:50-mixture of BCA Reagent B/BCA Reagent A. BCA standard dilutions and 
ddH2O served as reference solutions. All standards and samples were prepared in 
triplicate. Plates were incubated for 30 min at 37 °C before spectrometric measure-
ment at 562 nm using a Multiskan™ GO UV/Vis microplate spectrophotometer from 
Thermo Scientific.  
3.3.3 SDS-PAGE 
Proteins were separated according to their molecular weight by sodium dodecyl sul-
fate polyacrylamide gel-electrophoresis (SDS-PAGE) using 4 % stacking gels and 10 
% separation gels (Table 10). Protein samples (25 - 50 µg) were mixed with 10 µl 2x 









Table 10: SDS-gels 
Reagent 4 % stacking gel 10 % separation gel 
SDS-Gel buffer 2 ml 5 ml 
ddH2O 3.2 ml 5 ml 
Acrylamide 0.8 ml 5 ml 
APS 100 µl 100 µl 
TEMED 10 µl 10 µl 
3.3.4 Immunoblot 
Proteins separated by SDS-PAGE were transferred onto nitrocellulose membranes 
by semi-dry blot transfer. Nitrocellulose membranes as well as gels containing sepa-
rated protein samples were equilibrated in transfer buffer before use. Two layers of 
filter paper were soaked with transfer buffer and placed onto the anode of the blotting 
chamber. Then one piece of wet membrane was put onto the filter paper, followed by 
the gel and another two layers of transfer buffer-soaked filter paper. The upper layer 
was supposed to be in direct contact with the cathode on top of the chamber. Finally, 
the blotting chamber was closed and transfer was performed at 20 V for 30 min. 
After transfer to a nitrocellulose membrane, bound antigens were detected immuno-
logically by specific primary antibodies or antisera and horseradish peroxidase-
coupled (HRP) secondary antibodies. For this purpose, unspecific binding sites were 
first blocked with blocking solution at room temperature for 1 hour. Afterwards, mem-
branes were incubated with primary antibody or antiserum diluted in 1.5 % milk in 1x 
PBS-Tween at room temperature for 1 hour. Unbound antibodies were removed by 
washing the membrane three times with washing solution shaking for 5 min. For de-
tection of bound antibodies, membranes were incubated with HRP-coupled second-
ary antibodies diluted in 1.5 % milk in 1x PBS-Tween at room temperature for 1 hour. 
Unbound antibodies were washed away with washing solution three times shaking for 
5 min. Membranes were covered with ECL solution for detection of bound HRP-
coupled secondary antibodies. Emitted light was visualized by a transilluminator sys-
tem and software from Biorad.  
3.3.5 Blot stripping 
To allow de novo immunoblotting of already probed nitrocellulose membranes, bound 
antibodies had to be removed first. For this purpose, membranes were incubated in 









washed three times for 5 min before subjecting them to another round of immunoblot-
ting.  
3.3.6 Immunoprecipitation of subviral particles 
Subviral particles (SVP) in concentrated cell culture supernatants were immunopre-
cipitated with Protein G Sepharose by GE Healthcare. For this purpose, 400 µl of 
Protein G Sepharose were twice washed with 1 ml 1x PBS and centrifuged at 1000 g 
for 3 min after each washing step. Residual liquid was completely removed. 80 µl 
drained Protein G Sepharose was supplemented with 165 µg mAb 2F5, mAb 4E10 or 
goat348 α-TM serum. Antibody-protein G complexes were incubated on an overhead 
shaker at room temperature for 45 min. Subsequently, complexes were washed twice 
with 1 ml 1x PBS and centrifuged at 1000 g for 3 min after each washing step. 
Drained antibody-protein G complexes were supplemented with 50 µl concentrated 
cell culture supernatant. 1 ml 1x PBS was added to antigen-antibody-protein G com-
plexes and incubated on an overhead shaker at 4 °C over night. The following day, 
complexes were washed four times with 1x PBS and centrifuged at 1000 g for 3 min 
after every washing step. Last washing fractions (W4) were saved as controls for 
immunoblotting. Drained complexes were supplemented with 60 µl sample buffer and 
boiled at 95 °C for 5 min in order to elute immunoprecipitated antigens. Antigen-free 
beads were removed by centrifugation at maximum speed for 10 min. Supernatants 
containing immunoprecipitated antigens were directly applied to SDS-PAGE.  
3.4 Negative staining electron microscopy 
Concentrated cell culture supernatants that were supposed to contain subviral parti-
cles were applied to transmission electron microscopy. Electron micrographs (Figure 
31) were generated and kindly provided by Michael Laue and Gudrun Holland of the 
Robert Koch-Institute.  
Samples were adsorbed to Pioloform-coated, carbon-stabilized and alcianblue-
treated copper grids. The adherent particles were washed three times with distilled 
water. After negative staining with 1 % uranyl acetate, the samples were analyzed 
using a transmission electron microscope (EM 902, Zeiss, Oberkochen, Germany) at 
80 kV and the images were taken using a slow scan CCD-camera (Proscan, Scheu-









4 Results  
4.1 Subcloning of the FFV EnvG2 and chimeric FFV/HIV-1 EnvG2 x MPER1 
and MPER2 DNA sequences into a retroviral vector 
The FV env gene sequence encodes a splice donor-acceptor pair (SD/SA) flanking 
the membrane-spanning domain (MSD) of the transmembrane envelope protein 
(gp48). By that splice event, tas and bet are generated, while the MSD is deleted. 
Excision of the MSD results in synthesis of soluble Env protein that is C-terminally 
truncated and not incorporated into the cellular membrane. Thereby, subviral particle 
(SVP) formation is impaired due to reduced expression of membrane-bound Env pro-
tein after transient transfection of HEK293T cells with pBCenv constructs coding for 
FFV Env protein [95]. In order to increase incorporation of Env protein into the cellu-
lar membrane, the active SD/SA-pair was knocked out by silent mutagenesis [95]. 
The corresponding expression construct, pBCenvΔSASD, promoted increased incor-
poration of Env protein into the membrane and secretion of SVPs [95]. Additionally, 
two unique restriction sites recognized by BspEI and SgrAI were silently introduced 
adjacent to the membrane proximal external region (MPER). Similarly, two unique re-
striction sites recognized by BlpI and Bst1107I flanking the fusion peptide proximal 
region (FPPR) were silently introduced. The new pBCenvΔSASD backbone with 
those additional restriction sites was designated pBC EnvG2 (G2 = generation 2). 
The pBC EnvG2 backbone was used to replace the adjacent immunogenic regions in 
the FFV MPER (Figure 11) by the HIV MPER which naturally carries the 2F5 and 
4E10 epitopes. Two expression constructs, MPER1 x pBC EnvG2 and MPER2 x pBC 
EnvG2 were cloned that differ by a three amino acid-shift (Figure 15). That was 
based on the idea that altering the position in the predicted alpha-helical domain 
might increase the accessibility of the 2F5 and 4E10 epitopes [95].  
For simplification, hybrid MPER1 x EnvG2 and MPER2 x EnvG2 will be referred to as 










Figure 15. Amino acid sequences of the wild-type FFV MPER and chimeric FFV/HIV-1 MPER1 
and MPER2 proteins generated by Anne Bleiholder [95] 
The first line shows the C-terminal part of FFV TM (grey) with the epitopes identified by FFV TM 
epitope mapping (red) and the N-terminal part of the membrane-spanning domain (green). Below, the 
FFV/HIV-1 MPER1 and MPER2 sequences with the integrated HIV MPER (blue) sequence naturally 
carrying the 2F5 and 4E10 epitopes (underlined) are displayed.  
The EnvG2, MPER1 and MPER2 expression constructs were characterized as de-
scribed in the introduction section (Figure 12) [95]. After transient transfection of 
HEK293T cells, the EnvG2, MPER1 and MPER2 proteins were expressed and pro-
cessed as shown by the detection of gp130, gp48 and cell lysate-associated TMCL. 
The presence of the 2F5 and 4E10 epitopes in the MPER1 and MPER2 chimeras 
was confirmed by immunoprecipitation with both antibodies. The EnvG2, MPER1 and 
MPER2 constructs did not allow marker gene transfer but were released into cell cul-
ture supernatants as SVPs.  
Two different retroviral transfer plasmids served as target vectors for the EnvG2 and 
hybrid MPER1 and MPER2 DNA sequences: MP71-GFP [90] and pLenti-GFP natu-
rally containing eGFP (Figure 16).  
MP71-GFP is optimized for strong protein expression in lymphotrophic cell lines [90]. 
Protein expression is promoted by an improved 5’LTR derived from murine embryon-
ic stem cell virus (Figure 16A) [96]. Transgene expression is enhanced by an intron 
sequence located 5‘ of the transgene sequence and flanked by a SD/SA-pair that as-
sists nuclear export of transgene mRNA. Protein expression is further increased by a 
woodchuck hepatitis virus post-transcriptional regulatory element (PRE) positioned 3‘ 
of the transgene sequence. The PRE acts in cis by accumulation of mRNA levels and 
inhibition of mRNA degradation in the cytoplasm [106, 107]. In order to produce 
MP71 replication-incompetent viruses, Platinum-GP packaging cells were co-
transfected with MP71 expression plasmids and pMD2.G coding for vesicular stoma-
titis virus protein G (VSV-G). Platinum-GP cells are grown in the presence of blasti-









pLenti-GFP on the other hand, is a HIV-based lentiviral transfer plasmid [108]. In 
pLenti, protein expression is promoted by a strong CMV promoter (Figure 16B). Like 
MP71, pLenti also contains a PRE for increasing the steady-state level of transgene 
mRNA. Pseudotyping is enabled by a psi-packaging signal and further supported by 
the HIV-1 Rev-response element (RRE) which allows HIV-1 Rev-mediated transpor-
tation of viral mRNA to the cytoplasm. pLenti belongs to the 3rd generation packaging 
system that requires co-transfection of 4 plasmids in total for virus production [108]: a 
transfer plasmid (pLenti CMV GFP Puro (658-5)), an envelope plasmid (pMD2.G cod-
ing for VSV-G) and 2 packaging plasmids expressing Gag and Pol protein from one 






Figure 16. Retroviral vector maps of unmodified MP71-GFP (A) and lentiviral pLenti with the in-
corporated FFV EnvG2 gene (B) 
LTR: long terminal repeat, SD: splice donor, SA: splice acceptor, eGFP: enhanced green fluorescent 
protein, PRE: post-transcriptional regulatory element, AmpR: prokaryotic ampicillin resistance selec-
tion marker, CMV: cytomegalovirus promoter sequence, RRE: Rev-response element, A2 site: A2-
cleavage site, His-tag: histidin-tag. Subcloning of the chimeric FFV EnvG2 sequences into MP71 was 
done by homologous recombination replacing the eGFP gene, while insertion into pLenti was 5’ of the 
eGFP gene sequence by restriction digestion and ligation (the pLenti expression constructs were kind-
ly provided by Kerstin Hoffmann from the Berlin-Brandenburg Center for Regenerative Therapies - 









Another feature of the pLenti system is the production of fusion proteins originating 
from the transgene sequence and the eGFP gene sequence linked via an A2-site 
(Figure 17). During processing by the cell machinery, the dipeptide is auto-cleaved at 
the A2-cleavage site generating FFV EnvG2, FFV/HIV-1 MPER1 or MPER2 protein 
and functional eGFP. As a consequence, the fluorescence signal emitted by eGFP 
directly correlates with transgene expression. 
The pLenti FFV EnvG2 and chimeric pLenti FFV/HIV-1 MPER1 and MPER2 expres-
sion plasmids were generated and kindly provided by Kerstin Hoffmann of the Berlin-
Brandenburg Center for Regenerative Therapies - Charité University Medicine.   
 
 
Figure 17. Principle of transgenic protein expression promoted by pLenti 
Transgenic FFV EnvG2 protein and eGFP are translated as a dipeptide that is later auto-cleaved at 
the A2-site. Therefore, the fluorescence signal of eGFP is proportional to transgene expression.  
4.1.1 Generation of MP71 FFV EnvG2 and chimeric MP71 FFV/HIV-1 MPER1 
and MPER2 expression plasmids 
Subcloning of the FFV EnvG2 and chimeric FFV/HIV-1 MPER1 and MPER2 DNA 
sequences into MP71 was done by homologous recombination replacing the eGFP 
gene in MP71-GFP.  
For this purpose, MP71-GFP was linearized with the restriction enzyme EcoRI. To 
enable homologous recombination, the FFV EnvG2 and chimeric FFV/HIV-1 MPER1 
and MPER2 DNA sequences were PCR-amplified using the primers FFV Env Fu-
sion1 and FFV Env Fusion2. Those primers were designed to add 15 bp-extensions 
5’ and 3’ homologous to vector regions confining the eGFP gene in MP71-GFP. The 
pBC EnvG2, pBC MPER1 and pBC MPER2 expression plasmids [95] served as tem-
plates. After separation of the PCR mixtures by 1 % agarose gel-electrophoresis, the 









introduced into MP71 in a single reaction utilizing the In-Fusion® Kit from Clontech 
(see section 3.1.6). Subsequently, the reaction mixtures were transformed into 
NovaBlue GigaSingles™ Competent Cells for cloning. The following day, random 
colonies were picked for colony-PCR. The primers FFV TMH fwd and FFV Int se-
quencing primer rev were used resulting in amplicons of the N-terminal part of the 
FFV TM sequence with 491 bp in size. Analysis with 1 % agarose gel-electrophoresis 
revealed that most of the colonies were positive for the amplicons (Figure 18A). Five 
clones of each construct (EnvG2, MPER1 and MPER2) were chosen for a control di-
gest with EcoRI that was supposed to cut in the MP71 vector region and the SU se-
quence of the FFV Env gene. Clones that revealed one fragment with 360 bp in 
length after separation by 1 % agarose gel-electrophoresis where considered positive 






Figure 18. Subcloning into MP71 
A) Colony-PCR for screening of positive clones. Colony-PCR mixtures were directly applied to 1 % 
agarose gel-electrophoresis. Clones resulting in amplicons with 491 bp in length were considered 
positive (+) for either MP71 EnvG2 or chimeric MP71 MPER1 or MPER2, respectively. B) EcoRI-
control digest of clones that were positive after colony-PCR. Digested clones with a 360 bp-insert were 
assumed to carry the EnvG2, MPER1 or MPER2 gene sequence. Finally, sequencing was applied to 









4.1.2 Testing the FFV EnvG2 and chimeric FFV/HIV-1 MPER1 and MPER2 ex-
pression constructs for protein expression 
After successful subcloning, all FFV EnvG2 and hybrid FFV/HIV-1 MPER1 and 
MPER2 expression plasmids (pBC, pLenti, MP71) were tested for transgene expres-
sion. Therefore, HEK293T cells were transiently transfected with 1 µg pBC (positive 
control), 1 µg MP71 or 2 µg pLenti expression plasmid (EnvG2, MPER1, MPER2), 2 
µg pCF7 (infectious molecular clone of FFV, positive control) or 1 µg pEGFP-N3 
(negative control) using PEI as transfection reagent (see section 3.2.5). Cell lysates 
were prepared 48 hours after transfection and equal amounts applied to immunoblot-
ting using goat348 α-TM serum for antigen detection (Figure 19). After blot stripping, 
hybrid FFV/HIV-1 MPER1 and MPER2 antigens were reprobed with mAb 2F5 or mAb 
4E10.  
All expression constructs (pBC, MP71, pLenti) promoted wild-type FFV EnvG2 and 
hybrid FFV/HIV-1 MPER1 and MPER2 protein expression and processing as shown 
by the detection of gp130 and furin-cleaved gp48. As described by Bleiholder et al. 
before [95], the chimeric MPER1 and MPER2 expression constructs showed reduced 
protein expression and processing in comparison to the EnvG2 expression plasmids. 
Goat348 α-TM serum also detected a cell lysate-associated form of gp48 (TMCL) of 
35 - 40 kDa in length. It was found that TMCL is glycosylated but yet absent in viral 
and subviral particles. This might be explained by a possible loss of the C-terminus 
including the membrane-spanning domain that serves as a membrane anchor [95].  
Gp130 and processed gp48 were running above the 130 kDa and 48 kDa marker 
bands that is an indication for proper glycosylation of Env [95]. In order to verify gly-
cosylation of EnvG2, MPER1 and MPER2 proteins expressed by the pBC constructs, 
Bleiholder et al. treated cell lysates of transiently transfected HEK293T cells with En-
doglycosidase H (EndoH) [95]. Deglycosylation decreased the molecular weight with 
the result that gp130 was running at approximately 130 kDa and gp48 below 50 kDa, 
respectively [95]. In this way, the reduced electrophoretic mobilities of untreated 
gp130 and gp48 were ascribed to glycosylation.  
The fact that hybrid FFV/HIV-1 MPER1 and MPER2 proteins were recognized by 
mAb 2F5 and mAb 4E10 indicates that the HIV-1 MPER peptide naturally carrying 
the respective epitopes is present in all chimeric constructs. In comparison to 









cessed MPER1 gp48 but not MPER2 gp48. Likewise, detection of MPER1 by 4E10 
was stronger compared to MPER2. In contrast to 2F5, 4E10 also allowed detection of 
MPER2 gp48. Detection of MPER2 protein by 2F5 or 4E10 was weakest when ex-
pression was promoted by the pLenti MPER2 expression construct.  
 
Figure 19. FFV EnvG2 and chimeric FFV/HIV-1 MPER1 and MPER2 protein expressions are 
promoted by the pLenti and MP71 expression plasmids.  
1.6 x 10
5
 HEK293T cells were transfected with 1 µg pBC (positive control) [95] or MP71 expression 
plasmid (EnvG2, MPER1, MPER2), with 2 µg pLenti expression plasmid (EnvG2, MPER1, MPER2) or 
pCF7 (positive control) or 1 µg pEGFP-N3 as second negative control in addition to mock (no DNA). 
48 hours after transfection, cell lysates were prepared and analyzed by immunoblotting. Detection of 
antigens was performed either with goat348 α-TM serum, mAb 2F5 or mAb 4E10. Detection of β-actin 
with anti-actin antibody confirmed equal loading onto the SDS-gel. FFV EnvG2 or hybrid FFV/HIV-1 
MPER1 or MPER2 proteins were expressed and processed to different degrees, as shown by the de-
tection of gp130, gp48 and TM
CL
. The reduced electrophoretic mobilities of gp130 and gp48 in com-
parison to the 130 kDa and 55 kDa marker bands, respectively, indicated proper glycosylation. Chi-
meric MPER1 and MPER2 proteins were recognized by 2F5 and 4E10; whereas overall detection of 









4.2 Establishment of efficient protocols for virus production 
In order to generate cell lines stably expressing FFV EnvG2 or hybrid FFV/HIV-1 
MPER1 or MPER2 protein, single-round viruses for transduction had to be produced. 
Above all, transduction efficiencies correlate with virus titers. Therefore, transfection, 
virus production and concentration had to be optimized. For all experimental proce-
dures, the parental vectors MP71-GFP and pLenti-GFP were used to allow an easy 
read-out based on the detection of the fluorescence signal emitted by GFP.  
4.2.1 Transfection optimization for virus production 
Viral titers primarily depend on transfection efficiencies. Therefore, different amounts 
of MP71-GFP or pLenti-GFP plasmid DNA (pDNA) and different concentrations of 
transfection reagent, polyethylenimine (PEI), were tested in parallel; the assay in-
cluded DNA/PEI-ratios of 1:1, 1:2, 1:4 and 1:8. In this project, viral MP71 or pLenti 
transgene mRNA was pseudotyped with VSV-G. The high tropism of VSV-G [109] 
would allow screening of various target cells in further experiments (see section 4.3 
and 4.5.1).  
Platinum-GP packaging cells or HEK293T cells were seeded in separate 12-well 
plates with 40 % confluency. The following day, cells were transfected with 0.5 µg, 1 
µg and 2 µg MP71-GFP or pLenti-GFP. Platinum-GP cells stably expressing gag and 
pol were co-transfected with MP71-GFP and pMD2.G (VSV-G) in a ratio of 2:1; 
whereas HEK293T cells were co-transfected with pLenti-GFP, pMDLg/pRRE (gag 
and pol), pRSV-Rev (rev) and pMD2.G (VSV-G) in a ratio of 5:3.75:1.5:1. The cell vi-
abilities were examined 48 hours after transfection (Figure 20A). Subsequently, cell 
lysates were prepared and analyzed by immunoblotting detecting GFP expression 
with α-GFP HRP antibody (Figure 20B). The unconcentrated cell culture superna-
tants were directly used for transduction of HEK293T cells to allow determination of 
the relative virus productions in dependence of the transfection efficiencies (Figure 
20C).  
The viability-assay of the transfected cells revealed increased dying at higher con-
centrations of PEI (Figure 20A). When transfection was performed with 2 µg pDNA 
that clearly requires more PEI for transfection (DNA/PEI), viabilities were drastically 
reduced at DNA/PEI-ratios of 1:4 and 1:8. Viabilities of Platinum-GP cultures were 









Higher amounts of MP71-GFP DNA increased transfection efficiencies in Platinum-
GP cells as shown by stronger detection of GFP (Figure 20B). Detected GFP bands 
of Platinum-GP cell lysates were most distinct when transfection was with 0.5 µg, 1 
µg or 2 µg MP71-GFP and a DNA/PEI-ratio of 1:8, 1:4 or 1:2, respectively. In 
HEK293T cells, higher amounts of pLenti-GFP reduced the required concentration of 
PEI as shown by increased binding of GFP. Transfection with 2 µg pLenti-GFP and a 
DNA/PEI-ratio of 1:2 to 1:8  resulted in strongest GFP expression. 
Based on those results, transfections were carried out with 5 µg pDNA/1.6 x 106 cells 













Figure 20. Screening transfection conditions for optimal virus production 
1.6 x 10
5
 Platinum-GP cells or HEK293T cells were co-transfected with different amounts of MP71-
GFP or pLenti-GFP plasmid DNA (pDNA), respectively, and vectors required for virus production. For 
transfection with polyethyleneimine (PEI), various ratios of DNA/PEI were tested in parallel, as indicat-
ed. A) Viabilities depend on the amount of transfected pDNA and the DNA/PEI-ratio used for transfec-
tion. 48 hours after transfection, viabilities were determined as described in the method section. The 
bars represent viabilities of Platinum-GP (blue) and HEK293T cells (green). Increasing concentrations 
of PEI reduced viabilities. Platinum-GP cultures were more sensitive to PEI than HEK293T cells. B) 
Transfection efficiencies depend on the amount of transfected pDNA and the DNA/PEI-ratio. 48 hours 
after transfection, cell lysates were prepared and analyzed by immunoblotting. Relative transfection ef-
ficiencies were assessed by detection of GFP with α-GFP HRP antibody. Detection of β-actin with an-
ti-actin antibody confirmed equal loading of the cell lysates. In the case of MP71, equal transfection ef-
ficiencies with 0.5 µg, 1 µg and 2 µg MP71-GFP pDNA could be observed when the DNA/PEI-ratios 
were 1:8, 1:4 and 1:2, respectively. Transfection with pLenti-GFP was most effective with 2 µg pDNA 
and a DNA/PEI-ratio of 1:2 to 1:8. C) Transduction efficiencies depend on the amount of transfected 
pDNA and the DNA/PEI-ratio used for virus production. 48 hours after transfection, supernatants were 
harvested. 250 µl or 50 µl of unconcentrated supernatant (SN) were used for transduction of HEK293T 
cells in a 96-well plate. 72 hours after infection, transduction efficiencies (GFP pos. %) were deter-
mined by FACS. GFP pos. % ≙ % of events with FITC-height > lg 1. The bars represent the values of 
one experiment that directly correlated with the rate of virus production. Infection with MP71-GFP or 
pLenti-GFP virus is indicated in blue or green, respectively. The best virus production was by transfec-









4.2.2 Testing additives for enhanced virus production 
For maximizing virus production, two histone-deacetylase inhibitors, Na-butyrate and 
valproic acid, were tested as supplements in cell culture media.  
For this purpose, 1.6 x 105 Platinum-GP or HEK293T cells per well of two 24-well 
plates were transiently transfected with 0.5 µg MP71-GFP or pLenti-GFP and a 
DNA/PEI-ratio of 1:8 (see section 4.2.1). 24 hours after transfection, the culture me-
dia were supplemented with 1, 2, 5, 10, 15, 20, 30 or 50 mM (final concentrations) 
Na-butyrate or valproic acid. Viral culture supernatants were harvested after further 
48 hours and 50 µl unconcentrated aliquots directly used to infect 1.6 x 105 HEK293T 
cells. Transduction efficiencies were measured by FACS 72 hours after infection 
(Figure 21).  
MP71-GFP and pLenti-GFP virus production correlated nonlinearly with the tested 
concentrations of Na-butyrate and valproic acid. Compared to Na-butyrate, valproic 
acid was less effective in enhancing virus production. A 1.7-fold increase of transduc-
tion efficiency could be obtained by infection with MP71-GFP virus produced in the 
presence of 2 mM Na-butyrate (Figure 21A). On the other hand, transduction effi-
ciencies by pLenti-GFP virus increased 4-fold after supplementation with 50 mM Na-
butyrate (Figure 21B).  
According to those results, 2 mM and 50 mM Na-butyrate were applied 24 hours after 














Figure 21. Testing Na-butyrate and valproic acid for increased virus production 
0.5 µg MP71-GFP or pLenti-GFP were PEI-transfected (DNA/PEI-ratio was 1:8) into 1.6 x 10
5
 Plati-
num-GP or HEK293T cells, respectively. 24 hours after transfection, Na-butyrate and valproic acid 
were added to the culture medium in various concentrations, as indicated. After further 48 hours, 50 µl 
of unconcentrated viral culture supernatant were used to infect 1.6 x 10
5
 293T cells. 72 hours after in-
fection, transduction efficiencies (% GFP positive cells) were determined by FACS. % GFP positive 
cells ≙ % of events with FITC-height > lg 1. The bars represent the values of one experiment that di-
rectly correlated with the rate of virus production. Mock: no DNA, w/o: no additive. A) A significant cor-
relation between production of MP71 virus and concentration of Na-butyrate or valproic acid was ab-
sent. The best virus production was achieved with 2 mM Na-butyrate that resulted in a 1.7-fold in-
crease of transduction efficiency. B) Valproic acid significantly enhanced the pLenti virus production 
when concentrations were 1 to 5 mM. However, 50 mM Na-butyrate led to best virus production as the 











4.2.3 Testing methods to concentrate virus 
After having found optimal conditions for the production of MP71-GFP and pLenti-
GFP virus, two methods for concentrating virus were tested: polyethylene glycol 
(PEG) precipitation according to the protocol of Tiscornia et al. [105] and centrifuga-
tion. 
For this purpose, 1.6 x 107 Platinum-GP or HEK293T cells were transiently transfect-
ed with 26 µg MP71-GFP or pLenti-GFP and a DNA/PEI-ratio of 1:8 (see section 
4.2.1). Two days after transfection, 18 ml viral culture supernatants were harvested 
and filtered through a 0.45 µm filter. 7.5 ml cell-free supernatant were applied to PEG 
precipitation, 7.5 ml were centrifuged at 75500 g for 2 h and the residual 3 ml were 
stored at -20 °C. 150x virus concentrates were prepared by resuspending the respec-
tive pellets in 100 µl 1x PBS. 1.6 x 105 HEK293T cells in 24-well plates were infected 
with 10 µl unconcentrated cell-free viral supernatant or 10 µl virus concentrate ob-
tained by PEG or centrifugation. 48 hours after infection, the relative success of virus 
concentration was determined based on the transduction efficiencies measured by 
FACS (Figure 22).  
PEG precipitation seemed to be most suitable for concentrating MP71-GFP viruses 
since the transduction efficiency was approximately 13 % higher when compared to 
the centrifugation method. However, centrifugation was more promising for concen-
tration of pLenti-GFP virus because the transfection efficiency was 5 % higher in 
comparison to PEG precipitation.  
Those results did not show decisive differences between PEG precipitation and cen-
trifugation for virus concentration. Therefore, the method of centrifugation was ap-
plied in further experiments, since it is more feasible and yields virus pellets with 











Figure 22. Testing polyethylene glycol precipitation and centrifugation at 75500 g for virus 
concentration 
MP71-GFP or pLenti-GFP virus was produced by transfecting 1.6 x 10
7
 Platinum-GP or HEK293T 
cells with 26 µg MP71-GFP or pLenti-GFP, respectively, and a DNA/PEI-ratio of 1:8. 48 hours after 
transfection, viral culture supernatants were harvested. 7.5 ml of cell-free viral supernatant were ap-
plied to polyehtyleneglycol (PEG) precipitation or centrifuged at 75500 g for 2 h (Spin). Pelleted virus 
was resuspended in 100 µl 1x PBS. 1.6 x 10
5
 HEK293T cells were infected with 10 µl unconcentrated 
cell-free viral supernatant (SN) or virus concentrate, as indicated. 48 hours later, transduction efficien-
cies (% GFP positive) were determined by FACS. % GFP positive ≙ % of events with FITC-height > lg 
1. The bars represent the values of one experiment that directly correlated with virus titers.  Infection 
with MP71-GFP or pLenti-GFP virus is indicated in blue or green, respectively. Concentration of MP71 
virus by PEG precipitation was by 13 % more effective than centrifugation. On the other hand, pLenti-
GFP virus led to a 5 % higher transduction rate when centrifugation was applied.  
4.3 Optimization of retroviral infection 
Vectors pseudotyped with vesicular stomatitis virus protein G (VSV-G) have a broad 
host range [109]. However, infection rates may vary dependent on the target cell line. 
In order to find a target cell line that allows high transduction rates achieved by infec-
tion with VSV-G pseudotyped MP71 or pLenti virus, four different cell lines were test-
ed in parallel: 
 HEK293T cells that were used by Anne Bleiholder et al. for the production of 










 293F cells that are suspension cells derived from 293 cells. They are adapted to 
be cultured in serum-free expression media (e.g., FreeStyle™ 293 Expression 
Medium). Their characteristics would be advantageous because transduced sus-
pension 293F cells would constitute a larger culture surface releasing SVPs into 
serum-free medium. This could significantly simplify purification of SVPs. 
 Lymphotrophic C8166 cells that are grown in suspension. That feature turns 
them into interesting target cells because transduced C8166 cells would consti-
tute a high culture surface releasing SVPs (see 293F cells). Furthermore, their 
lymphotrophic character could be advantageous when transduction was with 
MP71 vectors since MP71 is optimized for protein expression in lymphotrophic 
cell lines [96].  
 CRFK cells that are feline kidney cells. They were tested because main parts of 
the epitope scaffold/the SVPs originate from feline foamy virus (FFV). Expression 
of FFV Env protein could be increasingly promoted in CRFK cells due to possible 
evolutionary adaption of FFV to its natural host, the cat [58]. 
Additionally, four infection conditions were tested in parallel for further optimization of 
retroviral infection with MP71 and pLenti virus:  
 infection with concentrated virus 
 polybrene added to the medium (8 µl/ml) (PB) 
 spinoculation at 1000 g at 37 °C for 1 hour (Spin) 
 polybrene added to the medium (8 µl/ml) and spinoculation at 1000 g at 37 °C for 
1 hour (PB+Spin) 
For this purpose, 1.6 x 107 Platinum-GP or HEK293T cells were transiently transfect-
ed with 26 µg MP71-GFP or pLenti-GFP and a DNA/PEI-ratio of 1:8 (see section 
4.2.1). 48 hours after transfection, viral supernatants were harvested and filtered 
through a 0.45 µm filter. Virus was concentrated hundred-fold by centrifugation at 










In order to test the four infection conditions mentioned above, 1 x 105 HEK293T, 
293F, C8166 or CRFK cells were infected with MP71-GFP or pLenti-GFP virus con-
centrate in 24-well plates. The volumes of virus concentrates were adapted so that 
estimated multiplicities of infections (MOI) were 1. One day after infection, the culture 
media were changed in order to mitigate toxic side-effects of polybrene. After further 
48 hours, FACS analysis of the transduced cells allowed comparison and evaluation 
of the infection conditions on the basis of the respective transduction efficiencies 
(Figure 23A) and mean fluorescence intensities (MFI) that indicate GFP expression 
per cell and correlate with integrated proviral copy numbers (Figure 23B).  
The highest transduction efficiencies and MFIs of HEK293T, C8166 and CRFK cells 
were obtained when PB + Spin was applied. However, MFIs of C8166 cells trans-
duced with MP71-GFP virus remained unaffected after assisted infection in any of the 
tested condition.  
Infection of 293F cells with MP71-GFP and pLenti-GFP virus resulted in diverse 
transduction efficiencies and MFIs, when compared to all other tested cell lines. Even 
though the transduction efficiency of MP71-GFP infection was increased by PB + 
Spin, MFIs could not be improved by any infection condition. As it was the case for 
the other cell lines, pLenti-GFP infection of 293F cells was more efficient than MP71-
GFP infection. However, neither polybrene nor spinoculation resulted in increased 
transduction efficiencies in 293F cells; only spinoculation elevated the MFI.  
Infection optimization by adding polybrene to the medium (8 µl/ml) in combination 
with spinoculation at 1000 g at 37 °C for 1 hour led to highest transduction efficien-
cies and MFIs of 3 of the 4 tested cell lines. Therefore, PB+Spin was used for infec-












Figure 23. Transduction optimization 
1 x 10
5
 HEK293T, 293F, C8166 or CRFK cells were transduced with concentrated MP71-GFP (blue 
bars) or pLenti-GFP (green bars, pL) virus as indicated. Estimated multiplicities of infections (MOI) 
were 1. Four infection conditions were tested in parallel: infection with concentrated virus, inf; infection 
in the presence of polybrene (8 µl/ml), PB; centrifugation at 1000 g at 37 °C  for 1 h, Spin; combination 
of polybrene (8 µl/ml) and centrifugation at 1000 g at 37 °C for 1 h, PB+Spin. 24 h after infection, the 
culture media were replaced. After a further 48 hours, transduced cells were analyzed by FACS. A) 
Transduction efficiencies (% GFP) in dependence of different infection conditions and cell lines. % 
GFP ≙ % of events with FITC-height > lg 1. The bars represent the values of one experiment. The 
highest transduction efficiencies of HEK293T, C8166 and CRFK cells after infection with MP71-GFP 
and pLenti-GFP virus were obtained when PB+Spin was used. 293F cells were the exception because 
the transduction efficiency with pLenti-GFP virus was highest when infection was performed with virus 
concentrate only. Infection of 293F cells with MP71-GFP virus was best when PB+Spin was used, but 
very inefficient when compared to transduction efficiencies of the other tested cell lines. B) Mean fluo-
rescence intensities (MFIs) in dependence of different infection conditions and cell lines. MFIs corre-
lated with average GFP expression per cell and multiple integrations of proviral DNA copies into the 
target genomes. MFI ≙ mean of FITC-heights > lg 1. AD: arbitrary units. The bars represent the values 
of one experiment. MFIs of pLenti-infected HEK293T, C8166 and CRFK cells were highest when 
PB+Spin was used. 293F cells transduced with pLenti-GFP virus resulted in highest MFI after centrif-
ugation. Infection with MP71-GFP virus led to higher MFIs of CRFK cells when compared to the other 
tested cell lines. Distinct increases in MFIs of MP71-infected 293F and C8166 cells after supported in-










4.4 Testing the established protocols for virus production and infection for 
applicability on the FFV EnvG2 and chimeric FFV/HIV-1 MPER1 and 
MPER2 constructs 
4.4.1 Real-time PCR for determination of virus titers 
In order to determine virus titers of MP71- and pLenti-FFV EnvG2 and hybrid 
FFV/HIV-1 MPER1 and MPER2 viruses, real-time PCR was applied. Since all MP71 
and pLenti vectors incorporate the PRE into target genomes, a real-time PCR pro-
gram was established that amplifies a short sequence of the PRE (Figure 16). There-
fore, the probe PRE2 Probe fwd and the primers PRE fwd and PRE2 rev were de-
signed to bind a sequence with 142 bp in length within the PRE sequence. Several 
concentrations of MgCl2 were tested for optimizing the sensitivity of the real-time 
PCR. An optimal condition and program was found (see section 3.1.5) which allowed 
detection of down to 101 initial plasmid DNA (pDNA) copies within 35 PCR-cycles 
(CT) (Figure 24A).  
The established protocol for real-time PCR was used to deduce two correlation 
curves (Figure 24B and 25) needed for calculations of virus titers:  
 CT / log copies of pDNA 
 Transduction efficiency / proviral copies 
For this purpose, plasmid standard dilution series of MP71-GFP and pLenti-GFP 
pDNA with 106, 105, 104, 103, 102, 101 and 100 copies/3 µl were prepared. Real-time 
PCR amplification of the dilution series (Figure 24A) allowed establishment of the 









dk  copieslogCT  (1) 
CT 
Cycle threshold; defined as the number of cycles required for 
the fluorescence signal to cross the fixed threshold [111].  
k Gradient; change of CT-value per copies. 






Figure 24. Real-time PCR of the MP71-GFP and pLenti-GFP dilution series 
Real-time PCR of MP71- or pLenti-GFP plasmid DNA dilution series with initial plasmid copy numbers 
of 10
6
 down to 10
0
 was performed as described in section 3.1.5. A) Analytical agarose gel-
electrophoresis of the real-time PCR-amplified pLenti-GFP and MP71-GFP dilution series. B) CT / log 
copy number-correlations of the MP71-GFP (blue) and pLenti-GFP (green) plasmid DNA dilution se-
ries.  
In order to establish the second calibration curve (transduction efficiency / proviral 
copies), transduction efficiencies and the corresponding CT-values of cells trans-
duced with MP71-GFP or pLenti-GFP virus had to be determined. As MP71-GFP and 
pLenti-GFP vectors lead to equivalent transductions (1 PRE/provirus), it was suffi-
cient to conduct only pLenti-GFP infections.  
For this purpose, 2.8 x 105 HEK293T cells were infected with 100 µl, 20 µl and 4 µl of 
unconcentrated cell culture supernatant containing pLenti-GFP virus with unknown ti-
ter. 72 hours after infection, transduction efficiencies were determined by FACS. Af-



























tion of the corresponding CT-values. Now, rearrangement of equation (1) to equation 
(2) allowed calculation of pLenti-GFP proviral copies integrated in 100 ng of trans-





Together with the transduction efficiencies obtained by FACS, the correlation be-
tween transduction efficiency and proviral copy number (Figure 25) based on equa-
tion (3) could be deduced.  
 
b
a copiespositive GFP %   (3)
 
% GFP positive Percentage of transduced cells. 
a Gradient; change of transduction efficiency per copies. 
b Exponent 
copies Proviral copy number (= copies proviral) 
 
 
Figure 25. Calibration curves obtained by real-time PCR with transduced genomic DNA 
The real-time PCR protocol was established for amplification of a short sequence of the PRE integrat-
ed into target genomes, regardless of the vector (MP71 or pLenti) used for transduction. Accordingly, it 
was sufficient to apply just pLenti-GFP infection for subsequent deduction of the MP71 as well as the 
pLenti calibration curves. Therefore, 2.8 x 10
5
 HEK293T cells were infected with 100 µl, 20 µl or 4 µl of 
unconcentrated pLenti-GFP viral culture supernatant with unknown titer. 72 hours after infection, 
transduction efficiencies (% GFP positive) were determined by FACS. % GFP positive ≙ % of events 
with FITC-height > lg 1. Genomic DNA was isolated and applied to real-time PCR for triplicate deter-
mination of proviral copies integrated. Finally, the correlations between transduction efficiencies (val-
ues of one experiment) and integrated MP71- or pLenti-GFP proviral copies (mean values) were es-









In order to calculate virus titers of MP71 and pLenti FFV EnvG2 and hybrid FFV/HIV-
1 MPER1 and MPER2 virus concentrates, 3.2 x 105 HEK293T cells were infected 
with 1 µl virus concentrate of unknown titer. 72 hours after infection, 100 ng gDNA 
were applied to real-time PCR. The obtained CT-values were used to calculate the 
corresponding proviral copies integrated by applying equation (2). The respective 
transduction efficiencies were determined with equation (3). Finally, application of 
equation (4) revealed virus titers (infectious units per ml) of MP71 and pLenti FFV 



















IU Infectious units 
corr. % GFP Corresponding transduction efficiencies calculated with equation (3).  




4.4.2 Applicability of the established protocols on the MP71-EnvG2 and pLen-
ti-EnvG2 constructs 
The MP71 and pLenti FFV EnvG2 and chimeric FFV/HIV-1 MPER1 and MPER2 ex-
pression plasmids differ from the MP71-GFP and pLenti-GFP plasmids by approxi-
mately 2.3 kb and 3 kb in length, respectively. Furthermore, possible toxic side-
effects due to over-expression of transgenic FFV Env protein might arise. According 
to those facts, the protocols for virus production that were established with the MP71-
GFP and pLenti-GFP plasmids needed to be tested for applicability on the EnvG2 
and chimeric MPER constructs.  
For this purpose, 7 x 104 Platinum-GP or HEK293T cells were transfected with 125 
ng or 250 ng total amount of DNA comprising MP71-EnvG2 or pLenti-EnvG2 expres-
sion plasmid and plasmids required for virus production as described in detail in sec-
tion 3.2.5. To screen for optimal PEI-transfection, different ratios of DNA/PEI (1:1, 
1:2, 1:4, 1:6 and 1:8) were tested in parallel (as described for MP71-GFP and pLenti-
GFP in section 4.2.1). Cell lysates were prepared 48 hours after transfection and 
equal aliquots analyzed by immunoblotting using goat348 α-TM serum for antigen 









In general, transfection with 250 ng DNA and the DNA/PEI-ratio of 1:8 resulted in 
strongest EnvG2 protein expression. Transfection with MP71-EnvG2 required fewer 
amounts of DNA and PEI. EnvG2 protein expression and processing promoted by 
MP71 could be detected after transfection with 125 ng DNA and DNA/PEI-ratios of 
1:4 to 1:8, as shown by the detection of gp130, gp48 and TMCL (Figure 26A). Trans-
fection with pLenti-EnvG2 required more DNA for detectable EnvG2 protein expres-
sion. After transfection with 125 ng pDNA and DNA/PEI-ratios of 1:6 and 1:8, only 
weak expression of gp130 and uncleaved gp130-GFP could be detected. Although 
transfection with 250 ng DNA resulted in stronger detection of EnvG2 protein expres-
sion promoted by pLenti, clear bands of processed gp48 and TMCL were still absent 
(Figure 26B). EnvG2 gp130 and gp48 expressed by MP71 or pLenti were properly 
glycosylated as shown by lower electrophoretic mobilities compared to the 130 kDa 






Figure 26. Transfection optimization with the MP71-EnvG2 and pLenti-EnvG2 constructs 
7 x 10
4
 Platinum-GP cells or HEK293T cells were co-transfected with 125 ng or 250 ng DNA (MP71-
EnvG2 or pLenti-EnvG2 pDNA and plasmids required for virus production; see section 3.2.5). For 
transfection with polyethyleneimine (PEI) various ratios of DNA/PEI were tested in parallel, as indicat-
ed. 48 hours after transfection, cell lysates were prepared and analyzed by immunoblotting. Detection 
of antigens was performed with goat348 α-TM serum. A) Immunoblot of Platinum-GP cells transfected 
with MP71-EnvG2. 250 ng DNA transfected with a DNA/PEI-ratio of 1:8 gave the best transfection effi-
ciencies as indicated by stronger binding of gp130, gp48 and TM
CL
. The reduced electrophoretic mo-
bilities of gp130 and gp48 in comparison to the 130 kDa and 55 kDa marker bands, respectively, indi-
cated proper glycosylation. ns: non-specific detection. B) Immunoblot of HEK293T cells transfected 
with pLenti-EnvG2. 250 ng DNA transfected with a DNA/PEI-ratio of 1:8 resulted in best transfection 
efficiencies as shown by the detection of gp130 and uncleaved gp130-GFP. However, Env protein ex-
pression was too low to allow detection of processed gp48 and TM
CL
. The reduced electrophoretic 
mobilities of gp130, gp130-GFP and gp48 in comparison to the 130 kDa and 55 kDa marker bands, 









200 µl of unconcentrated viral supernatant obtained from the cultures transfected 
with 250 ng DNA were used to transduce 3.2 x 105 293T cells. 72 hours after infec-
tion, genomic DNA was isolated and used for real-time PCR. Virus titers (IU/ml) were 
determined as described in detail in section 4.4.1.  
Transfection with the MP71-EnvG2 and pLenti-EnvG2 expression plasmids in a 
DNA/PEI ratio of 1:8 resulted in best virus titers (Figure 27), just as it was previously 
the case for MP71-GFP and pLenti-GFP virus production.  
 
Figure 27. Virus titers of FFV Env expression vectors in dependence of DNA/PEI-ratios 
7 x 10
4
 Platinum-GP or HEK293T cells were transfected with 250 ng MP71-EnvG2 or pLenti-EnvG2 
and various DNA/PEI-ratios, as indicated, in order to find an optimal condition for virus production. 48 
hours after transfection, 200 µl of unconcentrated viral culture supernatant were used to transduce 3.2 
x 10
5
 293T cells. 72 hours after infection, virus titers were determined in triplicate by applying real-time 
PCR (see section 4.4.1). The mean values and standard deviations of one experiment are shown. The 
bars represent the MP71-EnvG2 (blue) and the pLenti-EnvG2 (green) virus titers. Transfection with a 
DNA/PEI-ratio of 1:8 resulted in highest virus titers. 
Those data indicated that the protocols for virus production established with the 
MP71-GFP and pLenti-GFP vectors are generally applicable for the MP71- and pLen-










4.5 Production of subviral particles 
4.5.1 Finding a suitable target cell line for stable FFV EnvG2 and chimeric 
FFV/HIV-1 MPER1 and MPER2 protein expression 
After having established protocols for the production of MP71 and pLenti viruses, a 
cell line that is most suitable for transduction and stable FFV EnvG2 and chimeric 
FFV/HIV-1 MPER1 and MPER2 protein expression needed to be found. In that ex-
periment, the HEK293T, 293F, C8166 and CRFK cell lines were screened because 
of their characteristics mentioned in section 4.3.  
For this purpose, 1.6 x 107 Platinum-GP or HEK293T cells were transfected with 26 
µg MP71- or pLenti-EnvG2, MPER1 or MPER2, MP71-GFP or pLenti-GFP and a 
DNA/PEI-ratio of 1:8. 24 hours after transfection, 2 mM or 50 mM Na-butyrate were 
added to the Platinum-GP or HEK293T cultures, respectively. After a further 24 
hours, viral culture supernatants were harvested. The Platinum-GP or HEK293T cul-
tures were provided with fresh culture medium supplemented with 2 mM or 50 mM 
Na-butyrate, respectively. 24 hours later (72 hours after transfection), viral culture 
supernatants were harvested again. The 48 and 72 hours-supernatants were filtered 
through a 0.45 µm filter. Virus was concentrated hundred-fold by centrifugation at 
75500 g for 2 h and resuspending the viral pellets in an appropriate volume of 1x 
PBS. Related 48 and 72 hours-virus concentrates were pooled and stored at -20 °C. 
Afterwards, 50 µl of concentrated MP71- or pLenti-EnvG2, MPER1 or MPER2 virus 
or MP71-GFP or pLenti-GFP virus (negative controls) were used for infection of 1.4 x 
105 293F, C8166, 293T or CRFK cells. Cell lysates were prepared 72 hours after in-
fection and applied to immunoblotting detecting antigens with goat348 α-TM serum. 
Cell lysates of cells earlier transfected with pCF7 served as positive control (Figure 
28).  
293F cells transduced with MP71- or pLenti-EnvG2, MPER1 or MPER2 virus ex-
pressed Env protein as shown by weak detection of gp130 (Figure 28A). The expres-
sion of gp130 and uncleaved gp130-GFP proteins by pLenti MPER1 and MPER2 
was very low. Processing of Env protein could not be shown, since gp48 and TMCL 
remained undetected. However, proper glycosylation of gp130 and gp130-GFP was 










Env protein expression in infected C8166 cells was completely absent (Figure 28B). 
Env protein expression was not promoted in pLenti-infected HEK293T cells. In con-
trast, MP71-infected HEK293T cells expressed EnvG2, MPER1 or MPER2 protein as 
shown by the detection of gp130 (Figure 28C). Expression of EnvG2 gp130 protein 
was stronger than MPER1 and MPER2 gp130 protein so that processing of EnvG2 
could also be shown as indicated by the detection of gp48 and TMCL. Furthermore, 
gp130 was running above the 130 kDa marker band, indicating proper glycosylation. 
However, the protein smear of processed EnvG2 might be a result of differential and 
incomplete glycosylation levels.  
CRFK cells transduced with MP71-EnvG2, MPER1 and MPER2 virus showed strong 
expression and processing of Env protein as indicated by detection of distinct protein 
bands of gp130, gp48 and TMCL (Figure 28D). Proper glycosylation of Env was veri-
fied by the presence of only low protein smear but sharp protein bands of gp130 and 
gp48 running above the 130 kDa and 55 kDa marker bands, respectively. Again, Env 
protein expression in pLenti-infected CRFK cells remained undetectable.  
Those results suggested that CRFK cells infected with MP71-EnvG2, MPER1 or 
MPER2 virus are most suitable for FFV Env protein expression when compared to in-
fected 293F, C8166 and HEK293T cells. Consequently, the MP71-transduced CRFK 














Figure 28. Screening various cell lines for stable expression of FFV EnvG2 and chimeric 
FFV/HIV-1 MPER1 and MPER2 protein 
1.4 x 10
5
 293F, C8166, HEK293T or CRFK cells were infected with 50 µl of concentrated MP71- or 
pLenti-EnvG2, MPER1 or MPER2 virus or MP71-GFP or pLenti-GFP virus (negative controls) as indi-
cated. 72 hours after infection, cell lysates were prepared and analyzed by immunoblotting, along with 
cell lysates of pCF7-transfected cells as positive control. Detection of antigens was performed with 
goat348 α-TM serum. A) Immunoblot of transduced 293F cells. All constructs promoted FFV EnvG2 
and hybrid FFV/HIV-1 MPER1 and MPER2 protein expression as shown by the detection of gp130 
and uncleaved gp130-GFP encoded by the pLenti constructs. The reduced electrophoretic mobilities 
of gp130 and gp130-GFP in comparison to the 130 kDa marker band indicated proper glycosylation. 
Expression of processed gp48 and TM
CL
 was absent. ns: non-specific detection. B) Immunoblot of 
transduced C8166 cells. Expression by all MP71 and pLenti constructs was absent. C) Immunoblot of 
transduced 293T cells. Expression of FFV Env protein by the pLenti constructs was absent. All MP71 
constructs promoted FFV EnvG2 protein and hybrid FFV/HIV-1 MPER1 and MPER2 protein expres-
sion as shown by the detection of gp130. FFV EnvG2 protein was stronger expressed than MPER1 
and MPER2 proteins. Weak bands of processed FFV EnvG2 gp48 and TM
CL
 could be detected. The 
reduced electrophoretic mobilities of gp130 and gp48 in comparison to the 130 kDa and 55 kDa mark-
er bands, respectively, indicated proper glycosylation. ns: non-specific detection. D) Immunoblot of 
transduced CRFK cells. Expression of FFV Env protein by the pLenti constructs was absent. All MP71 
constructs promoted strong FFV EnvG2 and hybrid FFV/HIV-1 MPER1 and MPER2 protein expres-
sion and processing as shown by the detection of distinct bands of gp130, gp48 and TM
CL
. The re-
duced electrophoretic mobilities of gp130 and gp48 in comparison to the 130 kDa and 55 kDa marker 









4.5.2 CRFK cells transduced with MP71-EnvG2, MPER1 and MPER2 virus re-
lease subviral particles 
CRFK cells that were transduced with MP71-EnvG2, MPER1 and MPER2 virus seem 
to be suitable for strong expression of FFV EnvG2 and hybrid FFV/HIV-1 MPER1 and 
MPER2 protein (Figure 28D). Next, they had to be tested for subviral particle-release 
(SVP).  
For this purpose, 8 ml cell culture supernatant of confluent CRFK cultures infected 
with MP71-EnvG2, MPER1 or MPER2 virus were harvested. The cell-free superna-
tants that were supposed to contain SVPs were applied to ultracentrifugation on a 20 
% sucrose cushion. The protein pellets were resuspended in 80 µl sample buffer and 
directly analyzed by immunoblotting, along with cell lysates of the corresponding 
transduced CRFK cells as positive controls. Goat348 α-TM serum was used for anti-
gen detection (Figure 29).  
In all supernatants of EnvG2, MPER1 or MPER2 protein-expressing CRFK cultures, 
processed and properly glycosylated gp48 was present as shown by the detection of 
sharp protein bands running above the 55 kDa marker band. EnvG2 protein was 
more abundant when compared to MPER1 and MPER2 protein; even precursor 
EnvG2 gp130 could be detected.  
Those results gave a first indication that CRFK cells transduced with MP71-EnvG2, 












Figure 29. MP71-transduced CRFK cells release FFV EnvG2 and chimeric FFV/HIV-1 MPER1 
and MPER2 subviral particles into cell culture media 
Cell culture supernatants of confluent CRFK cultures transduced with MP71-EnvG2, MPER1 or 
MPER2 virus were harvested. 8 ml of cell-free supernatants were concentrated hundred-fold by ultra-
centrifugation on a 20 % sucrose cushion and analyzed by immunoblotting. Cell lysates of the corre-
sponding transduced CRFK cells served as positive controls. Detection of antigens was performed 
with goat348 α-TM serum. FFV EnvG2 and chimeric FFV/HIV-1 MPER1 and MPER2 SVPs were re-
leased into the supernatants as shown by the detection of processed gp48. EnvG2 SVPs were strong-
er released than MPER1 and MPER2 SVPs that were present in equal amounts. The precursor gp130 
of EnvG2 protein was also detected. The reduced electrophoretic mobilities of gp130 and gp48 in 
comparison to the 130 kDa and 55 kDa marker bands, respectively, indicated proper glycosylation. ns: 
non-specific detection.  
4.5.3 Characterization of EnvG2, MPER1 and MPER2 subviral particles by im-
munoprecipitation 
In order to test MP71-transduced CRFK cells on release of functional subviral parti-
cles (SVPs), immunoprecipitation was applied. To allow verification that the 2F5 and 
4E10 epitopes are accessible on the surface of native MPER1 or MPER2 SVPs, mAb 
2F5 and mAb 4E10 were used for immunoprecipitation.  
For this purpose, cell culture supernatants of confluent CRFK cultures transduced 
with MP71-EnvG2, MPER1 or MPER2 virus were harvested. The cell-free superna-
tants that were supposed to contain SVPs were ultracentrifuged on a 20 % sucrose 
cushion. Subsequently, the protein pellets were resuspended in an appropriate vol-
ume of 1x PBS containing protease inhibitor for two hundred-fold concentration. The 
concentrates were directly applied to immunoprecipitation. For immunoprecipitation 
of FFV EnvG2 SVPs and antigens from pCF7-transfected HEK293T cells (positive 









PBS (negative control) were submitted to immunoprecipitation with mAb 2F5 or mAb 
4E10. After washing the antigen-antibody-protein G complexes, the last washing frac-
tions were saved as controls for immunoblotting. Immunoprecipitated antigens were 
eluted from protein G by boiling in sample buffer. Finally, equal aliquots of the saved 
washing fractions (W4) and the immunoprecipitates were analyzed by immunoblot-
ting (Figure 30). In order to avoid cross-reactivity of secondary antibodies, Rat321-3 
α-TM serum was used to detect immunoprecipitated EnvG2 SVPs; immunoprecipi-
tated MPER1 and MPER2 SVPs were detected with goat348 α-TM serum.  
Native EnvG2 SVPs present in concentrated supernatants were immunoprecipitated 
by goat348 α-TM serum as indicated by the presence of furin-cleaved and properly 
glycosylated gp48 running above the 55 kDa marker band (Figure 30A). Likewise, 
mAb 2F5 and mAb 4E10 were able to immunoprecipitate MPER1 and MPER2 as 
shown by the detection of processed gp48 (Figure 30B, C). Again, reduced electro-
phoretic mobility compared to the 55 kDa marker band, verified proper glycosylation 
of gp48. Immunoprecipitation with mAb 2F5 resulted in higher enriched MPER1 
SVPs in relation to MPER2 SVPs. In return, immunoprecipitation of MPER2 SVPs 
was more efficient with mAb 4E10. All three immunoprecipitations could be consid-
ered very specific since antigens were completely absent in all washing fractions. 
The results of immunoprecipitation indicated that CRFK cells transduced with MP71-
















Figure 30. Immunoprecipitates of FFV EnvG2 and chimeric FFV/HIV-1 MPER1 and MPER2 sub-
viral particles 
Cell culture supernatants of confluent CRFK cultures transduced with MP71-EnvG2, MPER1 or 
MPER2 virus were harvested and concentrated two hundred-fold by ultracentrifugation on a 20 % su-
crose cushion. The concentrates were applied to immunoprecipitation. A) Immunoprecipitation of na-
tive FFV EnvG2 SVPs, 1x PBS (negative control) and a cell lysate of pCF7-transfected HEK293T cells 
(positive control) with goat348 α-TM serum. The immunoprecipitates (IP) and the fourth washing frac-
tions (W4) were analyzed by immunoblotting. Detection of antigens was performed with rat321-3 α-TM 
serum. FFV EnvG2 SVPs were immunoprecipitated by goat 348 α-TM serum as shown by the detec-
tion of gp48. The reduced electrophoretic mobility of gp48 in comparison to the 55 kDa marker band 
indicated proper glycosylation. B, C) Immunoprecipitation of hybrid FFV/HIV-1 MPER1 and MPER2 
SVPs and 1x PBS (negative control) with mAb 2F5 (B) or mAb 4E10 (C). The immunoprecipitates (IP) 
and the fourth washing fractions (W4) were analyzed by immunoblotting. Detection of antigens was 
performed with goat348 α-TM serum. Chimeric FFV/HIV-1 MPER1 and MPER2 SVPs were immuno-
precipitated by mAb 2F5 and mAb 4E10 as shown by the detection of gp48. MPER1 SVPs were more 
efficiently immunoprecipitated by mAb 2F5 than MPER2 SVPs (B); whereas MPER2 SVPs were high-
er enriched by mAb 4E10 than MPER1 SVPs (C). The reduced electrophoretic mobility of gp48 in 
comparison to the 55 kDa marker band indicated proper glycosylation. Immunoprecipitation was spe-









4.5.4 Transmission electron microscopy of concentrated cell culture superna-
tants supposed to contain subviral particles 
To further indicate that subviral particles (SVPs) are present in cell culture superna-
tants of CRFK cultures transduced with MP71-EnvG2, MPER1 and MPER2 virus, 
transmission electron microscopy was applied. 
For this purpose, MP71-transduced CRFK cultures (see section 4.5.2) were expand-
ed for SVP large-scale production in Corning® HYPERFlasks®. 500 ml cell-free su-
pernatants of confluent CRFK cultures that were supposed to release SVPs were 
harvested and ultracentrifuged on a 20 % sucrose cushion. Protein pellets were re-
suspended in 500 µl 1x PBS containing protease inhibitor. Concentrates were ana-
lyzed by Michael Laue and Gudrun Holland of the ZBS 4 (Advanced Light and Elec-
tron Microscopy) of the Robert Koch-Institute by negative staining electron microsco-
py (see section 3.4) (Figure 31).  
In general, two classes of particles were discovered in all samples. One class was 
more abundant, electron dense and about 100 nm in size. The other class was 
smaller in size (50 - 70 nm) with characteristic surface structures that resemble FV-
typical dense glycoprotein [83]. In order to demonstrate that one of those classes of 
particles are FFV SVPs, it would be necessary to apply electron microscopy after the 
method of immunogold-labeling utilizing, for example, goat348 α-TM serum, mAb 











Figure 31. Electron micrographs of concentrated subviral particle-like structures  
Supernatants of confluent CRFK cultures transduced with MP71-EnvG2, MPER1 or MPER2 virus 
were harvested and concentrated thousand-fold by ultracentrifugation on a 20 % sucrose cushion. 
FFV EnvG2 (A), FFV/HIV-1 MPER1 (B) and FFV/HIV-1 MPER2 (C). Two classes of particles could be 
found in all samples. One class was more abundant, electron dense and about 100 nm in size. The 














4.5.5 Optimization of subviral particle production 
DMEM HG was used in the experiments so far. However, the presence of 10 % FCS 
in cell culture supernatants could hamper SVP purification. For that reason, CRFK 
cells transduced with MP71-EnvG2 virus were subcultured in various commercially 
available serum-free expression media:  
 DMEM HG, FCS-free 
 RPMI, FCS-free 
 FreeStyle™ 293 Expression Medium  
 HyClone™ SFM4HEK293™ Medium 
 EX-CELL® VPRO 
Transduced CRFK cells grown in standard DMEM HG with 10 % FCS served as ref-
erence culture. 48 hours after subculturing, cells were analyzed by means of viabili-
ties, expression and processing of EnvG2 protein and release of EnvG2 SVPs. The 
viability-assay revealed that HyClone™ SFM4HEK293™ Medium and EX-CELL® 
VPRO increased the cell viabilities 2.4- and 2.2-fold, respectively (Figure 32A).  
8 ml cell-free supernatants were concentrated by ultracentrifugation on a 20 % su-
crose cushion. The protein pellets were resuspended in 80 µl sample buffer. In addi-
tion, cell lysates of the corresponding cells were prepared. Concentrates and lysates 
were analyzed in parallel by immunoblotting using goat348 α-TM serum for antigen 
detection (Figure 32B).  
In comparison, all tested media promoted EnvG2 protein expression and processing 
to similar degrees. Nevertheless, HyClone™ SFM4HEK293™ Medium and EX-
CELL® VPRO resulted in highest SVP-release, as indicated by strong detection of 












Figure 32. Testing various serum-free expression media for the purpose of large-scale produc-
tion of subviral particles 
CRFK cells transduced with MP71-EnvG2 virus were subcultured in various serum-free (-) culture me-
dia as indicated: DMEM HG, RPMI, FreeStyle™ 293 Expression Medium, HyClone™ SFM4HEK293™ 
Medium or EX-CELL® VPRO. As reference served transduced CRFK cells cultured in DMEM HG 
complemented with 10 % FCS (+). A) Viabilities in dependence of the tested expression media. 48 
hours after subculturing, viabilities were determined as described in the method section. The individual 
viabilities were put in relation to the viability of the reference culture. The bars indicate the values of 
one experiment. In comparison, HyClone™ SFM4HEK293™ Medium was most supportive to cells 
since it resulted in a 2.4-fold increase of viability. B) FFV EnvG2 protein expression and FFV EnvG2 
subviral particle-release (SVP) in dependence of the tested expression media. 48 hours after subcul-
turing, the cell-free supernatants were concentrated hundred-fold by ultracentrifugation on a 20 % su-
crose cushion. The concentrates were analyzed by immunoblotting, along with cell lysates of the 
transduced CRFK cells grown in the respective media. Detection of antigens was performed with 
goat348 α-TM serum. Compared to all other tested media, HyClone™ SFM4HEK293™ Medium and 
EX-CELL® VPRO promoted FFV EnvG2 SVP-release decisively as shown by the dominant protein 
bands of processed gp48 in the concentrates. The reduced electrophoretic mobilities of gp130 and 
gp48 in comparison to the 130 kDa and 55 kDa marker bands, respectively, indicated proper glycosyl-
ation.  
Due to unknown characteristics about the stability of SVPs in cell culture superna-
tants, an additional experiment should reveal an optimal harvest time point. There-
fore, four CRFK cultures transduced with MP71-EnvG2 virus were established in Hy-
Clone™ SFM4HEK293™ Medium. In order to find an optimal harvest time point, cell 
culture supernatants were harvested 24, 48, 72 or 96 hours after subculturing, re-
spectively. 8 ml of the respective cell-free supernatants were concentrated by ultra-









80 µl sample buffer and directly analyzed by immunoblotting using goat348 α-TM se-
rum for antigen detection (Figure 33). The cell lysates of the CRFK cells collected at 
the same time points as the corresponding cell culture supernatants served as refer-
ence.  
It turned out that harvesting the cell culture supernatants at different time points did 
not accumulate SVPs after 24 hours as shown by equal detection of gp48. However, 
enriched contaminants could be observed in the 96 hour-concentrate as indicated by 
the detection of TMCL running below gp48.  
 
Figure 33. Amount of subviral particles in cell culture supernatants at different time points 
CRFK cells transduced with MP71-EnvG2 virus were four times subcultured in HyClone™ 
SFM4HEK293™ Medium. 24, 48, 72 or 96 hours after subculturing, the respective cell culture super-
natants were harvested and applied to ultracentrifugation on a 20 % sucrose cushion for hundred-fold 
concentration. The concentrates were analyzed by immunoblotting, along with the corresponding cell 
lysates of the subcultured CRFK cells collected at the same time points as the respective cell culture 
supernatants. Detection of antigens was performed with goat348 α-TM serum. Harvesting cell culture 
supernatants at different time points revealed no accumulation or depletion of released subviral parti-
cles as shown by equal detection of gp48 in the respective supernatants. Gp130 and gp48 had re-
duced electrophoretic mobilities when compared to the 130 kDa and 55 kDa marker bands, respec-
tively, that is an indication for proper glycosylation.  
The results indicated that HyClone™ SFM4HEK293™ Medium as well as EX-CELL® 
VPRO are very suitable expression media for large-scale production of FFV SVPs. 
No change in the amount of SVPs could be observed after 24 hours of subculturing. 
In order to avoid accumulation of contaminants, supernatants should be harvested 
within 24 and 72 hours. One can conclude that MP71-transduced CRFK cells cul-
tured in HyClone™ SFM4HEK293™ Medium allow daily harvesting of SVP-









4.5.6 Do lysine-to-arginine mutations in FFV Elp increase SVP-release? 
It is known that FV Env undergoes several post-translational modifications throughout 
cellular processing. Previous studies on PFV Env revealed five lysine residues (K14, 
K15, K18, K34 and K53) located in the N-terminal part of the envelope leader peptide 
(Elp) that are targets for ubiquitination (Figure 34A). Those ubiquitination sites are 
apparently responsible for limited subviral particle-release (SVP) since lysine-to-
arginine mutations of all five residues (R14, R15, R18, R34 and R53) increased SVP-






Figure 34. Deletion of the ubiquitination sites in PFV Elp leads to increased subviral particle-
release [87, 88] 
A) PFV Env. LP: envelope leader peptide, h: hydrophobic region, SU: surface protein, FP: fusion pep-
tide, TM: transmembrane envelope protein, MSD: membrane spanning domain, K: lysine residue, R: 
arginine residue. Also shown are the approximate locations of the ubiquitination sites (K14, K15, K18, K34 
and K53) of the wild-type PFV LP (wt) and the inactivated ubiquitination sites (R14, R15, R18, R34 and 
R53) of the mutated PFV LP (ΔUbi). B) Relative influence of the deletions of the ubiquitination sites in 
the PFV LP on subviral particle-release (SVP). SVP-release is increased more than 10-fold after dele-
tion of all five ubiquitination sites.  
Whether FFV Elp also carries ubiquitination sites, is currently unknown. Based on the 
assumption that ubiquitination does happen in FFV Elp, deletion of presumptive 
ubiquitination sites might also increase FFV SVP-release. By checking the sequence 
of the N-terminal part of FFV Elp, five lysine residues could be found (K10, K20, K24, 









genesis-PCR. The expression plasmids pBC EnvG2, MPER1 and MPER2 [95] 
served as templates and the K-to-R mutations were introduced by the primers Elp1 
fwd, Elp1 rev, Elp2 fwd and Elp2 rev. The expression plasmids carrying all five K-to-R 
mutations in the FFV Elp sequence were called pBC Elp-EnvG2, pBC Elp-MPER1 
and pBC Elp-MPER2.  
 
Figure 35. Amino acid sequences of PVF Elp wt, FFV Elp wt and FFV Elp ΔUbi carrying the mu-
tations K10R, K20R, K24R, K45R and K48R 
The upper amino acid sequence indicates the N-terminal region of the wild-type PFV Envelope leader 
peptide (Elp). PFV Elp naturally contains five lysine residues that are targets of ubiquitination (red K14, 
K15, K18, K34 and K53). Also shown are the N-terminal sequences of the wild-type FFV Elp and the mu-
tated FFV Elp ΔUbi. The five wild-type lysine residues (Ks) are highlighted in red, while the lysine-to-
arginine mutations (Rs) are depicted in blue.  
In order to test the impact of the mutated FFV Elp gene sequence on EnvG2 protein 
expression and SVP-release, 3 x 106 HEK293T cells were transfected with 15 µg 
pBC EnvG2, pBC Elp-EnvG2 or pCF7 Bet-His as positive control. 72 hours after 
transfection, two fractions of cell pellets were prepared to allow subsequent gene ex-
pression analysis by reverse transcription-PCR (RT-PCR) and immunoblotting.   
One fraction was used for investigation of Elp-EnvG2 gene transcription. Therefore, 
cellular RNA was isolated and applied to non-quantitative RT-PCR along with pBC 
EnvG2, pBC Elp-EnvG2 and pCF7 Bet-His plasmid DNA (pDNA) as positive controls. 
For amplification of the whole Env gene sequence, the primers FFV EnvG2 fwd and 
FFV EnvG2 rev were used. Figure 36A shows the cDNA-amplicons separated by 1 % 
agarose gel-electrophoresis. RT-PCR of isolated RNA resulted in two distinct ampli-
cons that were smaller than the single amplicons coming from the expression plas-
mids (pDNA). One of the two cDNA-amplicons obtained from the pCF7 Bet-His RNA-
isolate (positive control) was smaller in length than the respective cDNA-amplicons of 
EnvG2 and Elp-EnvG2 RNA-isolates. In comparison, transcription of the Elp-EnvG2 
gene seemed to be less promoted than EnvG2 gene transcription as shown by the 









The second cell fraction was used for the preparation of cell lysates that were ana-
lyzed by immunoblotting working with goat348 α-TM serum (Figure 36B) for antigen 
detection. pBC Elp-EnvG2 promoted Elp-EnvG2 protein expression, processing and 
proper glycosylation as shown by the detection of gp130 and gp48 running above the 
130 kDa and 55 kDA marker bands. Elp-EnvG2 protein expression was reduced.  
In order to determine the impact of the five K-to-R mutations on SVP-release, the 
cell-free supernatants of the transfected HEK293T cultures were ultracentrifuged on 
a 20 % sucrose cushion. Subsequently, protein pellets were resuspended in an ap-
propriate volume of sample buffer for hundred-fold concentration and directly ana-
lyzed by immunoblotting (Figure 36C) using goat348 α-TM serum for antigen detec-
tion. In comparison to EnvG2 SVPs, lower amounts of Elp-EnvG2 SVPs were re-
leased into the supernatants as shown by the weaker detection of processed gp48.  
Those results indicated that the five lysine-to-arginine mutations incorporated into the 
N-terminal region of FFV Elp significantly decreased expression of Env protein. As a 
consequence, the release of Elp-EnvG2 SVPs was reduced when compared to 
EnvG2 SVPs. According to those observations, the pBC Elp-EnvG2, MPER1 and 




















Figure 36. pBC FFV Elp-EnvG2 promotes reduced Env gene transcription, protein expression 
and subviral particle-release  
3 x 10
6
 HEK293T cells were transfected with 15 µg pBC EnvG2, pBC Elp-EnvG2 or pCF7 Bet-His 
(positive control). 72 hours after transfection, cells were pelleted and analyzed. A) Non-quantitative re-
verse transcription-PCR (RT-PCR) of EnvG2 and Elp-EnvG2 mRNA transcripts. RNA was isolated 
from the transfected cells and RT-PCR-amplified, along with pBC EnvG2, pBC Elp-EnvG2 and pCF7 
Bet-His plasmid DNA (pDNA) as positive controls. Amplified cDNA was applied to 1 % agarose gel-
electrophoresis. Two cDNA-amplicons were obtained with EnvG2, Elp-EnvG2 and pCF7 Bet-His RNA-
isolates that were smaller than the single amplicons of the expression plasmids. One cDNA-amplicon 
of the positive control pCF7 Bet-His RNA-isolate was smaller than the respective cDNA-amplicon of 
the EnvG2 and Elp-EnvG2 RNA-isolates. Transcription of the Elp-EnvG2 gene seemed to be weaker 
than EnvG2 gene transcription. B) EnvG2 and Elp-EnvG2 protein expression. Cell lysates of the trans-
fected HEK293T cells were prepared and analyzed by immunoblotting. Detection of antigens was per-
formed with goat348 α-TM serum. Env protein expression by pBC Elp-EnvG2 was lower compared to 
pBC EnvG2. The reduced electrophoretic mobilities of gp130 and gp48 in comparison to the 130 kDa 
and 55 kDa marker bands, respectively, indicated proper glycosylation. ns: non-specific detection. C) 
EnvG2 and Elp-EnvG2 subviral particles (SVP) released into the cell culture supernatants. Cell-free 
supernatants of the transfected HEK293T cultures were concentrated hundred-fold by ultracentrifuga-
tion on a 20 % sucrose cushion. Concentrates were analyzed by immunoblotting. Detection of anti-
gens was performed with goat348 α-TM serum. By comparison, lower amounts of Elp-EnvG2 SVPs 










5.1 Transfection optimization for high virus titers 
The experiments on transfection optimization confirmed findings of previous studies 
showing that the plasmid size is inversely correlated with the transfection efficiency 
[112] and thus detrimental to virus titers [113]. Additionally, the concentration of the 
transfection reagent plays a crucial role as indicated by the results of the screening 
for optimal transfection conditions (Figure 20). Actually, the outcome of that experi-
ment seemed to be contradictory on first sight. Higher amounts of MP71-GFP and 
pLenti-GFP pDNA (2 µg/1.6 x 105 cells) resulted in increased detection of GFP ex-
pression in the cell lysates (Figure 20B), but the highest virus titers were obtained 
with lower DNA-levels (0.5 µg/1.6 x 105 cells) (Figure 20C). This might be explained 
by the fact that 2 µg DNA required four-fold more transfection reagent, polyethylene-
imine (PEI). However, viabilities were drastically reduced at higher concentrations 
(Figure 20A) that is not quite surprising because PEI is known to inflict damages on 
cytoplasm membranes [114]. Transfection with 0.5 µg DNA per 1.6 x 105 cells and a 
DNA/PEI-ratio of 1:8 seemed to reflect a balanced compromise between the toxicity 
of PEI and the required DNA amount for virus production.  
The outcome of the experiment on the transferability of the transfection protocols on 
MP71-EnvG2 and pLenti-EnvG2 confirmed that the plasmid size is decisive for trans-
fection efficiencies (Figure 26). For comparison: MP71-GFP is ~ 6 kb and MP71-
EnvG2 is ~ 8.3 kb in length; while pLenti-GFP is ~ 8.4 kb and pLenti-EnvG2 is ~ 11.7 
kb in length. When the amount of transfected DNA was doubled, EnvG2 protein ex-
pression promoted by MP71-EnvG2 (Figure 26A) and pLenti-EnvG2 (Figure 26B) 
was significantly increased. Probably, transfection of pLenti-EnvG2 would even re-
quire more DNA. Transfection with 250 ng DNA increased detection of gp130 and 
uncleaved gp130-GFP but it was still low compared to EnvG2 protein expression 
promoted by MP71-EnvG2; processed gp48 was not expressed. Comparison of the 
MP71-EnvG2 and pLenti-EnvG2 virus titers (Figure 27) further verifies the hypothesis 
that larger proviral DNA leads to lower virus titers. However, one must consider that 
the MP71 and pLenti transfer plasmids belong to different packaging systems. In con-
trast to MP71-vectors, pLenti-vectors require co-transfection of three additional plas-









fected for MP71- or pLenti virus production, comparatively lower pLenti virus titers 
could also be a result of less amount of pLenti-vector available for packaging.  
Nevertheless, the pLenti packaging system is optimized for virus production as indi-
cated by infections with pLenti-GFP virus. In the experiment on increasing virus pro-
duction with additives, transduction efficiencies after infections with pLenti-GFP virus 
were between ~ 10 to 45 % compared to ~ 3 to 5 % resulting from MP71-GFP virus 
infections (Figure 21). The efficiency of pLenti-GFP virus infection was further indi-
cated by the data obtained from transduction optimization through assisted infection; 
~ 70 to 100 % transduction efficiencies could be obtained (Figure 23A). Presumably, 
those results display the fact that the pLenti packaging system works with a protocol 
that is established and optimized for virus production. While the pLenti packaging 
system uses three plasmids expressing Gag, Pol and accessory proteins at prede-
fined ratios, MP71 virus production was performed with a packaging cell line. In this 
project, Platinum-GP cells were used which constantly express the packaging factors 
gag and pol at default rates. Accordingly, diverse transduction efficiencies between 
MP71- and pLenti-infected cell cultures are not surprising. Platinum-GP cells are also 
293 cells but, regarding their comparably reduced viabilities, it has to be added that 
they need to be grown under blasticidin-selection in order to maintain gene expres-
sion of gag and pol. Drug selection might constitute a substantial burden that could 
hamper virus production and increase their vulnerability to PEI (Figure 20). Further-
more, the cytotoxicity of VSV-G [115, 116] should also be taken into account of which 
comparatively higher amounts were applied for pseudotyping MP71-vectors (see sec-
tion 3.2.5).  
Interestingly, supplementation with Na-butyrate and valproic acid, that also have 
clear cytotoxic properties [117-119], showed to be supportive in virus production at 
completely different concentrations (Figure 21). Obviously, MP71-GFP and pLenti-
GFP virus production was less supported by valproic acid than Na-butyrate even 
though valproic acid was shown to be superior in promoting protein expression after 
transient transfection of 293 cells [120]. Additionally, virus production was non-linear 
with increasing concentrations of Na-butyrate or valproic acid. That might be ex-
plained by the fact that both chemicals interfere in biochemical pathways regulating 
the cell-cycle by directly and/or indirectly activating and/or de-activating several regu-
latory proteins [117, 119]. Therefore, it can be speculated that those diverse results 









5.2 MP71-infection of CRFK cells seemed to be most suitable for the estab-
lishment of cell lines stably expressing EnvG2, MPER1 and MPER2 pro-
tein 
In a previous study, it was shown that polybrene and spinoculation enhance lentiviral 
transduction efficiencies [121]. Accordingly, it was not surprising that polybrene and 
spinoculation in combination resulted in enhanced infections as shown by the results 
of the transduction optimization experiments (Figure 23). As already mentioned 
above, infection with pLenti-GFP virus seems to be more feasible, presumably due to 
high virus titers. Infection of 293T, C8166 and CRFK cells with virus concentrate only 
resulted in transduction efficiencies between 80 and 100 %. Therefore, infection en-
hancement by polybrene and spinoculation was insignificant. In contrast, MP71-GFP 
virus infections could be considerably boosted by polybrene and spinoculation. Using 
polybrene or spinoculation alone resulted in 20 to 30 % increase of transduction effi-
ciencies in 293T, C8166 and CRFK cells. When polybrene and spinoculation were 
used in combination, the transduction efficiency in 293T cells could even be in-
creased by approximately 70 %.  
Efficacy of polybrene and spinoculation was further confirmed by determination of the 
mean fluorescence intensities (MFI) that were considered to correlate with multiple 
integrations of retroviral vectors (Figure 23B). MFIs in 293T, C8166 and CRFK cells 
could be increased by several 100 to 2000 arbitrary units (AU) when polybrene and 
spinoculation were used in combination during infection with MP71-GFP or pLenti-
GFP virus. However, a change of MFIs in C8166 cells after assisted infection with 
MP71-GFP virus could not be observed.  
Interestingly, the four tested infection conditions led to diverse results in 293F cells. 
Transduction with MP71-GFP virus could be improved by a maximum of 18 % when 
polybrene and spinoculation were used in combination. However, the highest trans-
duction efficiency with pLenti-GFP virus was achieved with virus concentrate only. As 
it was the case for C8166 cells, any of the tested conditions did not increase MFIs af-
ter infection with MP71-GFP virus; whereas MFI was significant higher after pLenti-
GFP virus infection with spinoculation. The results of that experiment showed that in-
fection efficiencies depend on the target cell line. Nevertheless, it was surprising that 
transduction of 293F cells was inconsistent with the infection rates of the other tested 









also tended to adhere onto the bottom of culture plates during incubation and 
spinoculation (data not shown). Accordingly, 293F cultures would rather resemble 
293T cultures. 293F cells are standardly grown in serum-free FreeStyle™ 293 Ex-
pression Medium. It can be speculated that some unknown factors supplemented to 
the medium are possibly detrimental to infections with VSV-G pseudotyped vectors. 
However, it has to be considered that the experiment and measurements were each 
conducted only once. Repetitions might allow more convincing insights on infections 
of 293F cells.  
Surprisingly, when infections were performed with MP71 FFV EnvG2 or hybrid 
FFV/HIV-1 MPER1 or MPER2 virus, 293F cells seemed to be more suitable com-
pared to C8166 cells (Figure 28A, B). While 293F cells showed weak expression of 
precursor gp130, Env protein expression was even entirely absent in C8166 cells. At 
least Env protein expression promoted by the MP71 expression vectors was ex-
pected because MP71 vector is optimized for protein expression in lymphotrophic cell 
lines like C8166 [96]. In comparison to both suspension cell lines, infections of the 
adherent 293T and CRFK cells with MP71 viruses were more effective (Figure 28C, 
D). Especially CRFK cells showed very strong Env protein expression. Presumably, 
MP71 virus titers were too low to obtain comparable transduction efficiencies in the 
suspension cell lines 293F and C8166; that would be in line with previous reports 
about transduction of suspension cells [122]. When infection was performed with 
pLenti FFV EnvG2 or hybrid FFV/HIV-1 MPER1 or MPER2 virus, 293F cells were the 
only cell line in the panel that showed Env protein expression. This and the fact that 
Env protein expression promoted by pLenti vectors was totally absent in adherent 
293T and CRFK cells (Figure 28C, D) are in stark contrast to transduction efficiencies 
obtained with pLenti-GFP virus (Figure 23). It has to be considered that the titer of 
pLenti EnvG2 virus was lower than the titer of MP71 EnvG2 virus (Figure 27). Pre-
sumably, the titers of pLenti viruses were too low for detectable transductions. An-
other reason for those observations could be possible degradation of the gp130-GFP 
fusion peptide. This cannot be excluded because gp130-GFP is more complex than 
gp130 expressed by the MP71 expression constructs. Misfolding might influence cor-
rect processing of the A2-site of gp130-GFP (Figure 17) and target the fusion peptide 









5.3 Transduced CRFK cells release chimeric FFV/HIV-1 MPER1 and MPER2 
SVPs that are recognized by 2F5 and 4E10 
In her PhD thesis, Anne Bleiholder demonstrated distinct levels of FFV EnvG2 and 
FFV/HIV-1 MPER1 and MPER2 protein expression and subviral particle release upon 
transient transfection of HEK293T cells. Compared to MPER1 and MPER2 protein, 
release of EnvG2 protein into supernatants was greater promoted (Figure 12) [95]. In 
this project, her findings were confirmed by parallel transfection of HEK293T cells 
with the pBC, pLenti and MP71 EnvG2 and MPER expression constructs (Figure 19); 
although transduced CRFK cells revealed equal protein expression (Figure 28D, 29). 
Analysis of the supernatants obtained from the transduced CRFK cultures verified 
reduced MPER1 and MPER2 SVP-release (Figure 29). It was suggested that replac-
ing the respective DNA sequence in FFV TM with the HIV-1 MPER DNA sequence 
might result in mRNA transcripts with reduced stability or enhanced misfolding of Env 
protein which is subsequently targeted for degradation [95].  
Interestingly, detection of MPER1 protein expression with mAb 2F5 and mAb 4E10 
was stronger when compared to MPER2 protein, as it was already previously shown 
with mAb 2F5 [95]. In an earlier study it was demonstrated that 2F5 and 4E10 recog-
nize their respective epitopes in linear form after denaturation by SDS-PAGE [123-
125]. Thus, different detection of MPER1 and MPER2 protein was quite surprising, 
since both chimeras carry the very same HIV-1 MPER sequences. It can be specu-
lated that more stringent denaturing conditions would have been necessary in order 
to resolve unknown remaining secondary structures or dimerization products caused 
by the three amino acid shift that might reduce the accessibilities of both epitopes. 
However, mAb 2F5 and mAb 4E10 were able to bind the respective epitopes in na-
tive conformation as shown by immunoprecipitation. Both antibodies specifically rec-
ognized and precipitated MPER1 and MPER2 SVPs present in concentrated cell cul-
ture supernatants (Figure 30B, C). Successful immunoprecipitation thus confirmed 
the accessibility of the 2F5 and 4E10 epitopes on the surface of the released hybrid 
MPER1 and MPER2 SVPs that is key for binding by B-cell receptors. However, it 
should be mentioned that B-cell activation depends on activation by T-cells which 
are, in turn, activated by B-cells as antigen-presenting cells. B-cells introduce anti-
gens as small peptides bound to class II major histocompatibility complex proteins to 









epitopes in the absence of a lipid environment (see section 1.1.4 and 1.3) in order to 
allow successful induction of immune responses against the HIV-1 MPER.  
After immunoprecipitation of EnvG2 SVPs, the precursor protein gp130 was weakly 
detected (Figure 30A). By contrast, gp130 was completely absent in the MPER1 and 
MPER2 precipitates. It was previously demonstrated that FFV EnvG2 protein, unlike 
chimeric FFV/HIV-1 MPER1 and MPER2 proteins, mediates cell fusion upon transi-
ent transfection of 293T cells [95]. Fusogenic activities or cytopathic effects (CPE) 
(Figure 9) result in release of free gp130 protein due to cell lysis. Accordingly, 
Bleiholder’s findings would explain the detection of co-precipitated gp130. 
Negative staining electron microscopy of EnvG2, MPER1 and MPER2 SVP concen-
trates revealed two classes of particles present in concentrated cell culture superna-
tants (Figure 31). One class was more electron-dense and about 100 nm in size. The 
other class was smaller and had a surface with characteristics resembling glycopro-
tein. The member of the electron microscopy department assumed that the smaller 
particles are probably SVPs; whereas the larger particles would be too dense for 
SVPs which do not contain Gag. The morphological appearance of the larger parti-
cles thus suggests the presence of virus or virus-like particles (containing Gag and 
Env) in cell culture supernatants. As a matter of fact, it was previously demonstrated 
that CRFK cells produce an endogenous virus [127, 128]. Concerning immunization 
studies, it would be advantages to gain more insight on the characteristics of the 
larger particles before immunization because their presence in SVP concentrates 
could potentially influence the outcome of the immunization studies.  
5.4 Some expression media increase EnvG2 protein expression 
For the purpose of successful immunization studies using subviral particles (SVPs), 
several micrograms of antigen should be available in high purity. Hence, large-scale 
production of SVPs needed to be optimized in order to increase the yield after ensu-
ing purification. Different commercially available serum-free expression media were 
tested that should facilitate later large-scale production and purification. The results 
displayed in Figure 32 demonstrated significant support of culture viability together 
with high release of EnvG2 protein into supernatants by the application of HyClone™ 
SFM4HEK293™ Medium or EX-CELL® VPRO. In fact, viability was boosted 2.4- or 









As depicted in Figure 32B, EnvG2 protein expression was apparently only minimally 
stronger promoted by HyClone™ SFM4HEK293™ Medium or EX-CELL® VPRO, 
whereas processing even seemed to be reduced when compared to the other tested 
media. However, together with the strong detection of gp48 in the concentrated cul-
ture supernatants, it can be assumed that SVP-release was considerably enhanced. 
High concentration of gp48 in the supernatants due to fusogenic activity of EnvG2 
could be excluded, since no TMCL was detected [95].  
Harvesting cell culture supernatants at different time points revealed no accumulation 
of SVPs (Figure 33) that was different than expected. It is unclear if the HyClone™ 
SFM4HEK293™ Medium that was used for culturing the transduced CRFK cells 
leads to reduced stability of SVPs. Presumably, the boosted viability and SVP-
release by HyClone™ SFM4HEK293™ Medium is only short-term before cells even-
tually start dying. This would also explain the detection of TMCL in the 96-hour super-
natant (Figure 33). Accordingly, cell culture supernatants should be concentrated be-
tween 24 and 72 hours after subculturing. If the harvest time point is later, accumula-
tions of undesired TMCL occur.  
5.5 Lysine-to-arginine mutations in FFV Elp decrease subviral particle release 
Introduction of five lysine-to-arginine mutations (K-to-R) in the N-terminal region of 
the FFV envelope leader peptide (Elp) (Figure 35) clearly reduced EnvG2 protein ex-
pression (Figure 36). Those results indicated that the ubiquitination sites of PFV Elp 
are not conserved in FFV Elp. While deletion of the ubiquitination sites by K-to-R mu-
tations in PFV Elp increased PFV subviral particle (SVP) release (Figure 34), equiva-
lent mutations in the FFV Elp DNA sequence obviously decreased stability of Env 
mRNA transcripts (Figure 36A).  
Why RT-PCR with isolated RNA resulted in two amplicons is still unexplained (Figure 
36A). The primers that were used should allow amplification of the full-length Env 
gene sequence as demonstrated by parallel RT-PCR-amplification of the respective 
plasmids. Interestingly, even RNA from cells transfected with the infectious molecular 
clone of FFV (pCF7) led to two cDNA-amplicons. However, the smaller fragment of 
pCF7 was apparently shorter in length than the smaller fragments of EnvG2 or Elp-
EnvG2. Analysis of the respective cell lysates by immunoblotting proved that Env 









those amplicons partially correspond to the SU and the TM DNA sequences. Hence, 
the fact that pCF7 resulted in still two but one smaller cDNA-amplicon, could be due 
to the fact that pCF7 encodes unmodified Env; the SD/SA-pair of the Env gene se-
quence is deleted in pBC EnvG2 and pBC Elp-EnvG2 [95]. As a consequence, 
spliced mRNA transcripts of the EnvG2 gene encoded by pCF7 are actually expected 
to be shorter. Nevertheless, those results showed that R-to-K mutations in FFV Elp 
result in decreased SVP-release (Figure 36C) because of reduced EnvG2 protein 
expression (Figure 36A, B).  
5.6 Immunization studies will reveal the potential of hybrid FFV/HIV-1 SVPs to 
induce neutralizing antibodies against HIV-1 
In this project, an efficient protocol for the production of FFV-based subviral particles 
(SVPs) carrying the HIV-1 MPER sequence was established. The protocol is based 
on the strategy of generating cell lines stably expressing FFV EnvG2 or hybrid 
FFV/HIV-1 MPER1 or MPER2 protein after retroviral infection.  
The respective coding sequences were subcloned from the pBC EnvG2, pBC 
MPER1 and pBC MPER2 expression plasmids [95] into two different retroviral trans-
fer plasmids (MP71 and pLenti). Afterwards, generation of single-round viruses and 
infection of target cells was optimized. Stably transduced CRFK cells were then used 
to optimize the large-scale production of EnvG2, MPER1 and MPER2 SVPs. It was 
finally shown that the MPER1 and MPER2 SVPs carry the 2F5 and 4E10 epitopes 
that are accessible to the respective antibodies.  
Further experiments will give rise to efficient protocols for large-scale purification of 
SVPs. The antigens should be eventually confirmed by transmission electron micros-
copy using the method of immunogold-labeling. Final immunization studies utilizing 
the hybrid FFV/HIV-1 MPER1 or MPER2 SVP antigens in a DNA-prime/SVP-boost 
regimen will evaluate their potential for the induction of 2F5 and 4E10-like antibodies 









6 Zusammenfassung  
Durchschnittlich 2,5 Jahre nach einer HIV-Infektion entwickeln ungefähr 10 - 30 % 
der infizierten Patienten breitneutralisierende Antikörper. Zwei solcher Antikörper sind 
2F5 und 4E10, die die membrannahe externe Region (MPER) des transmembranen 
Hüllproteins gp41 binden. Studien haben ergeben, dass das nichtpathogene Retrovi-
rus feline foamy virus (FFV), ähnlich der 2F5 und 4E10-Epitope, ebenfalls immuno-
gene Regionen im membrannahen Bereich von TM (gp48) mit zweiteiliger Anord-
nung aufweist. Anders als bei anderen Retroviren, ist das FFV Env-Protein in der La-
ge sich ohne weitere Virusproteine als subviraler Partikel (SVP) von der Zytoplas-
mamembran abzuschnüren. In einer vorangegangen Arbeit wurden durch Ersetzen 
der äquivalenten Sequenzen die 2F5 und 4E10-Epitope in die FFV Env-kodierende 
Gensequenz eingefügt. Nach Transfektion von HEK293T-Zellen, wurden hybride 
FFV/HIV-1 SVPs, auf deren Oberfläche die 25F und 4E10 Epitope exponiert sind, in 
die Zellkulturüberstände abgegeben. Um jedoch deren Potential als Impfstoff gegen 
Infektionen durch HIV-1 mittels Immunisierungsstudien in Ratten bestimmen zu kön-
nen, sind größere Mengen dieser chimären SVP-Antigene erforderlich. Im Rahmen 
dieser Masterarbeit wurden effiziente Protokolle zur Großproduktion von SVPs etab-
liert. Zuerst wurden die entsprechenden Sequenzen in retrovirale Transfervektoren 
subkloniert. Um diese mit Vesicular stomatitis virus-Protein G zu pseudotypisieren, 
wurden anschließend die Produktion und das Konzentrieren von infektiösen Viren 
systematisch optimiert, um möglichst hohe virale Titer zu erhalten. Verschiedene 
Zelllinien wurden dann testweise für die Produktion von SVPs stabil transduziert, wo-
bei sich CRFK-Zellen als optimale SVP-Produzenten erwiesen. Nachdem durch Im-
munopräzipitation der Antigene mit den monoklonalen Antikörpern 2F5 und 4E10 ge-
zeigt wurde, dass die entsprechenden Epitope zugänglich sind, wurde die erfolgrei-
che SVP-Produktion mittels Transmissionselektronenmikroskopie nach "Negativkon-
trastierung“ bestätigt. Schließlich wurde die Produktion von SVPs nochmalig durch 
das Testen einer Reihe kommerzieller Expressionsmedien optimiert, wobei erstmals 
durch das Anwenden von Corning® HYPERFlasks® SVPs im größeren Maßstab 
produziert wurden. Durch die hier etablierten Protokolle für die Großproduktion von 
hybriden FFV/HIV-1 SVPs, die die 2F5 und 4E10 Epitope an ihrer Oberfläche prä-
sentieren, kann diese neuartige FFV-basierende rekombinante Strategie für ein Anti-
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